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Assembly of inorganic nanoparticles (NPs) can give rise to novel collective 
properties due to the coupling between adjacent subunits, which are not accessible from 
individual nanoparticles. Among them, hybrid polymer-inorganic nanoassemblies 
(HPINs) are particularly attractive by combining the complementary strengths of 
inorganic NPs and polymers. This dissertation describes the design of HPINs with 
elaborately tailored physicochemical properties and the applications of HPINs in tumor 
diagnosis and therapy. 
First, we introduced the design principles and representative morphologies of 
HPINs. Size, shape, surface charge and coatings are crucial properties to be considered 
before the design of HPINs. Among various types of HPINs, we focused on the hybrid 
vesicles assembled from polymer-tethered inorganic NPs due to their synergistic 
properties that surpass their constituent components. We also summarized recent 
  
advances in the development of HPINs as attractive platforms for cancer imaging and 
therapy. 
Second, we developed an enzyme-free signal amplification technique, based on 
gold vesicles encapsulated with Pd−Ir NPs as peroxidase mimics, for colorimetric assay 
of disease biomarkers with significantly enhanced sensitivity. 
Third, we introduced a universal approach to attach amphiphilic block copolymers 
onto oleic acid or/and oleylamine capped NPs to trigger their assembly. Various NPs 
including Fe3O4, Cu9S5, MnO and upconversion NPs were assembled into hollow 
vesicles with novel physicochemical properties for a variety of biomedical applications. 
Finally, we described the fabrication of nanosized magneto-vesicles comprising 
tunable layers of densely packed superparamagnetic iron oxide nanoparticles (SPIONs) 
in membranes via cooperative assembly of polymer-tethered SPIONs and free 
poly(styrene)-b-poly(acrylic acid). Due to the high packing density of SPIONs, the 
magneto-vesicles showed enhanced signal in magnetic resonance imaging as well as 
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Chapter 1: Introduction 
 
Part of this chapter is adapted from the manuscript “Shaoyi Zhang†, Kuikun Yang†, Jie 
He, Wan-Kyu Oh and Zhihong Nie#, Polymer/inorganic Nanohybrids for Cancer 
Imaging and Therapy” to be submitted to Nano Today. († Equal contribution) 
 
Self-assembly refers to the process by which small building blocks such as 
molecules and colloid particles spontaneously organize into larger or ordered structures 
without external intervention.1 Molecular self-assembly is extraordinarily common in 
nature and in daily life and it plays numerous important roles in the formation of various 
complex structures. For example, membranes of living cells originate from the self-
assembly of phospholipids. Viruses are assembled from protein and nucleic acid. Soap 
bubbles are self-assemblies of small molecule surfactants. Materials scientists have 
aspired to replicate assembly principles found in nature to design and fabricate artificial 
materials with hierarchical structures and tailored properties for a variety of 
applications. Compared with top-down methods such as photo-lithography, self-
assembly is a simple and low-cost bottom-up approach to create complex nano- or 
micro-sized functional materials from pre-existing building blocks. With the rapid 
development in colloidal particle synthesis, researchers have become increasingly 
interested in using colloidal nanoparticles (NPs) as building blocks to fabricate 
functional assemblies with controlled structures. However, it remains challenging to 
organize colloidal NPs into desired assemblies as conventional molecular building 
blocks. It is, therefore, essential to develop novel strategies for the assembly of 






1.1 Molecular self-assembly 
Understanding the principles of molecular self-assembly is the foundation for 
studying and designing more complex assembly systems of colloidal NPs. A wide 
range of molecules such as, lipids, surfactants, dendritic molecules and block 
copolymers (BCPs), can be used to form supramolecular nanostructures at different 
conditions. These molecules often consist of one or more hydrophobic tails and a 
hydrophilic head group to make them amphiphilic. The amphiphilicity enables their 
self-assembly into various nanostructures, such as spherical micelles (spheres), 
cylindrical micelles (cylinders), bicontinuous structures, lamellae and vesicles in 
selective solvents. The morphology of assemblies is primarily determined by the 
packing parameter, p = v/aolc, where v is the volume of the hydrophobic segment, ao is 
the cross-sectional area of the head group, and lc is the length of the hydrophobic 
segment. Spherical micelles are generally formed when p is less than 1/3; cylinders are 
assembled when 1/3 < p < 1/2; flexible lamellae or vesicles when 1/2 < p < 1; and 
planar lamellae when p = 1. If p is larger than 1, inverted structures could be observed.2 
 
1.1.1 Self-assembly of amphiphilic lipids 
Amphiphilic lipids are the most important building blocks for self-assembly. They 
are generally composed of a hydrophilic head and a hydrophobic tail region (Figure 
1.1). The amphiphilic structure of lipids induces the aggregation of these molecules 
into larger structures with well-organized position and orientation in water. In addition, 
the structural diversity of lipids with different polarities, lengths and charged groups 





lamellar bilayers and vesicles (liposomes), which have already found applications in 
different fields including biosensing, bioimaging and drug delivery.3,4 
 
 
Figure 1.1. Schematic illustration of self-assembling of amphiphilic lipids into 
liposomes. Reproduced from Ref. [4] with permission of Dovepress. 
 
1.1.2 Self-assembly of amphiphilic block copolymers (BCPs) 
Amphiphilic BCPs, in which hydrophobic and hydrophilic polymer blocks are 
covalently bound to each other, are another commonly used building blocks for self-
assembly. The self-assembly of amphiphilic BCPs in selective solvents generates 
assemblies with a variety of morphologies including spheres, cylinders, lamellae, 





synthesis have allowed the rationale design of BCPs with high uniformity, purity and 
significant chemical and structural diversity. Compared with small-molecule 
assemblies, polymer assemblies exhibit higher stability and durability due to their 
mechanical properties, as well as higher complexity due to the flexibility and 
deformability of BCP chains. The assembly structures of BCPs have found broad 
applications in such as microelectronics, photoelectric materials, catalysts, bioimaging 
and drug delivery.5,6 
 
 
Figure 1.2. Schematic illustration of self-assembling of amphiphilic BCPs into 
spherical micelles, cylindrical micelles, and vesicles according to their packing 







1.2 Hybrid polymer-inorganic nanoassemblies (HPINs) 
Although assemblies of amphiphilic molecules have received considerable 
attention in both academic researches and practical applications, the rapidly rising 
demand for new materials drives the design of nanostructures with increasing 
complexity and new functionalities. Hybrid nanoscale materials comprising two or 
more components in one system may exhibit advanced or new properties that surpass 
their constituent components, due to the combination or synergistic effect of the 
subunits. Among them, hybrid polymer-inorganic nanoassemblies (HPINs) are 
particularly attractive as they naturally combine the complementary strengths of 
inorganic NPs (e.g., intrinsic optical and magnetic properties, etc.) and polymers (e.g., 
biocompatibility, biodegradability, chemical stability, tunable responsiveness to 
external stimuli such as, heat, light, and sound wave, etc.). As a result, HPINs have 
emerged as attractive platforms for tumor management by offering early diagnosis, 
high resolution imaging, real time therapeutic monitoring, selective tumor targeting and 
efficient tumor growth inhibition.7 
 
1.2.1 Design principles of HPINs for biomedical applications 
To achieve optimal theranostic performance, it is crucial to deliver sufficient 
amount of HPINs to the right time and location. The in vitro and in vivo fate of HPINs 
is governed by their physicochemical properties such as size, shape, charge and surface 







Figure 1.3. Physicochemical properties that determine in vivo performance of HPINs. 
 
(i) Size. The effects of size have been studied extensively with spherically shaped 
particles for their biomedical applications. The ideal size of NPs for in vivo applications 
falls in the range between 5 and 200 nm.8-10 Particles smaller than 5 nm are rapidly 
cleared from the circulation through extravasation or renal clearance, while particles 
larger than 200 nm tend to be trapped by Kupffer cells in reticuloendothelial systems 
(RES). On the other hand, tumor vessels tend to be more permeable than normal vessels, 
which allows passive accumulation of NPs in tumor tissues (enhanced permeability and 
retention effect). However, small particles (<5nm) can be readily secreted from tumor 
tissues even after they accumulate around tumor. Particles that are larger than 200 nm 
are believed not able to penetrate through the leaky vessels.  
(ii) Shape. Although the shape of particles is known to play an important role in 
their in vivo fate, the exact effects of NP shape on biological actions are still under 
debate, due to the variation in the sample standards and intrinsic complexity of the 
biological system. For example, the shape of particles is considered to directly 





highest cellular uptake, followed by spheres, cylinders, and cubes.11 On the contrary, 
in studies with sub-100 nm NPs, spheres have higher cellular internalization than rods. 
Additionally, in this size range, increasing the aspect ratio of nanorods (NRs) decreases 
the cell uptake of NPs.  
(iii) Charge. Surface charge of NPs also determines their cellular uptake, 
biodistribution and interaction with other biological environments. Generally, 
positively charged NPs are considered to be more easily internalized than neutral and 
negatively charged NPs. This can be attributed to the electrostatic attraction between 
negatively charged membrane and positively charged NPs which favors their adhesion 
onto the cell membrane, leading to enhanced uptake compared with neutral and 
negatively charged NPs.12 This process, in fact, can be complicated when serum or 
other biological species are presented due to the quick absorption and formation of 
protein corona on NP surface. As the surface charge determines corona composition, 
the interaction between NPs and cells also varies from study to study. In this regard, 
cellular uptake of the NPs by phagocytes or target cells should be tested prior to in vivo 
administration of HPINs. 
(iv) Surface coating. The surface coating can influence biological performance of 
NPs such as circulation time, biodistribution and cellular uptake. PEGylation of NPs 
has been widely used to prolong their in vivo circulation time by the stealthing effect. 
Functional ligands that can specifically target certain cellular populations can also be 
introduced to HPINs by surface modification. Various ligands such as antibodies, 
aptamers, peptides and small molecules have been introduced onto the surface of 





targeting, responsiveness to specific microenvironment can be imparted to HPINs by 
utilizing appropriate surface coating. For instance, HPINs could be programed to 
respond to light, heat, pH or enzymes for various biomedical applications. 
 
1.2.2 Representative morphologies of HPINs 
Depending on the spatial distribution of inorganic NPs and polymers, there are six 
distinct representative morphologies of HPINs that can be classified into three 
categories: 1) solid NPs consisting of polymeric shell loaded with one or more 
inorganic NPs as core(s) (I, II); 2) polymeric micelles loaded with one or more 
inorganic NPs (III); and 3) NP-loaded hollow vesicles: polymer vesicles internally 
loaded with inorganic NPs (IV), polymer vesicles embedded with inorganic NPs in the 
hydrophobic membrane (V), and hybrid vesicles assembled from polymer tethered 







Figure 1.4. Representative morphologies of polymer/inorganic nanohybrids that are 
summarized into six main categories: polymer-coated single inorganic NPs (I), 
inorganic NP-loaded polymer particles (II), inorganic NP-loaded polymeric micelles 
(III), polymer vesicles internally encapsulated with inorganic NPs (IV), polymer 
vesicles embedded with inorganic NPs in the membrane (V), and hybrid vesicles  
assembled from polymer-tethered inorganic NPs (VI). The major difference between 
(V) and (VI) is the density and ordering of NPs in the vesicular membranes.   
 





The simplest HPINs are polymer-coated inorganic NPs, in which inorganic NPs 
are enclosed in polymer shells. Constructing a layer of polymers on the surface of 
inorganic NPs has multiple benefits for biomedical applications. The polymer coatings 
can improve the stable dispersion and biocompatibility of inorganic NPs in intracellular 
microenvironments and prevent possible dissociation of toxic inorganic ions. Efficient 
targeting and internalization of NPs can be achieved by designing polymers with 
functional groups for specific targeting capability or for the further conjugation of 
targeting moieties. Most importantly, the polymers can be also used to absorb or 
conjugate cargos within the nanostructures through noncovalent interactions or 
covalent bonds. 
As an efficient method to coat polymeric thin films with desired properties on 
various NP surfaces, electrostatic layer-by-layer (LbL) self-assembly has been 
developed and widely used to design functional nanocarriers for bioimaging and drug 
delivery.14 The coating of inorganic NPs with polymer layers relies on the alternate 
adsorbing of oppositely charged polyelectrolytes on the surface of inorganic NPs.15 The 
thickness of each layer can be adjusted by tuning the ionic strength of the 
polyelectrolyte solution. A thicker layer can be obtained by using a solution of higher 
ionic strength, due to the induced loops or tails formation of polymers. A solution of 
low ionic strength facilitates the flat conformation of polymers on NP surfaces to form 
a thinner layer. 
In LbL assembly, the positive charge of polymers is usually contributed by the 
ionization of amino- and imino-containing groups, such as poly(allylamine) (PAL), 





from pendant sulfonate groups or carbonate groups, such as poly(styrenesulfonate), 
poly(acrylic acid) (PAA), etc. The composition of the polymer layers is not limited to 
two components, as long as the polymers possess opposite charges of appropriate 
strength. With the appropriate choice of polymers and functional ligands, the resulting 
customized solid polymer coated single NPs can meet various requirements from 
surface chemistry, biocompatibility, controlled permeability, loading of therapeutic 
agents to optical or magnetic properties.16 
Different from noncovalent coating of polymer layers via LbL technique, 
polymeric shells can be grown directly on the surface of NPs to form HPINs. Initially, 
inorganic NPs are attached with initiators or chain transfer agents, followed by the 
growth of polymer chains extending out from the NPs surface. For effective attachment, 
the initiator or chain transfer agent should bear functional groups with strong affinity 
to the surface of NPs, such as thiol for noble metal NPs (e.g., Ag, Au) and quantum 
dots (QDs), silane for silica NPs, carboxylate or phosphonate for iron oxide NPs 
(IONPs), etc.17 Various surface initiated polymerization techniques have been used to 
grow polymer chains, such as nitroxide-mediated polymerization (NMP), reversible 
addition-fragmentation transfer polymerization (RAFT), and atom transfer radical 
polymerization (ATRP).18,19 
Coating polymer shells on the surface of inorganic NPs presents as a facile and 
efficient way to prepare HPINs from diverse combinations of polymers and inorganic 
NPs. Polymer-coated inorganic NPs show advantages on flexible size tuning of NPs in 
the 10-100 nm size range which benefits their accessibility to and within disseminated 





challenging to improve the loading capacity and control the intrinsic properties of 
individual polymer-coated inorganic NP. Thus, more elaborately designed HPINs are 
required for enhanced efficacy in biomedical applications. 
 
Inorganic NP-loaded polymer particles 
Another type of HPINs is inorganic NP-loaded solid polymeric particles in which 
multiple inorganic NPs are homogeneously or spatially arranged in a polymer matrix. 
There are two major approaches for encapsulating NPs in polymer matrix: (i) 
polymerization in the presence of inorganic NPs and (ii) emulsification of polymers in 
a solution of inorganic NPs. The former one usually involves solution-phase 
polymerization (e.g., emulsion polymerization) in the presence of inorganic NPs. In a 
typical emulsion polymerization-based synthesis, inorganic NPs are first treated with 
hydrophobic coupling agents, in order to tailor the suitable affinity between the 
monomer and the surface of NPs, followed by the initiation of polymerization to 
achieve NP-loaded polymer particles. HPINs are also fabricated by emulsification of a 
mixture of polymers and NPs followed by solvent removal. In this approach, a solution 
of mixed polymer and inorganic NPs are emulsified into nano- or micro-sized droplets 
in an immiscible solvent (e.g., water). The solvent in droplets is subsequently removed 
to generate final products by evaporation, salting out, emulsification diffusion, dialysis, 
or supercritical fluid technology.20-22 Emulsifying agents such as ordinary 
phospholipids, PEGylated lipids and poly vinyl alcohol (PVA) are usually used to 
stabilize the emulsion droplets and prevent the coalescence of droplets during the 





tens to hundreds of nm (mostly below 200 nm), which is dependent on a series of 
parameters, including the temperature, chemical composition and concentration of 
surfactant.26 Using this method, a variety of inorganic NPs with different sizes, shapes, 
and compositions (e.g., iron oxide, QDs, noble metal NPs) have been loaded in 
polymeric matrix of homopolymers or BCPs.7,22 To achieve the homogenous 
dispersion of inorganic NPs in the matrix, inorganic NPs are usually treated by 
hydrophobic coupling agents so that the surface ligand of inorganic NPs should be 
compatible with (one block of) the polymer matrix. Since all NPs are embedded within 
the polymeric particle, the biodistribution and pharmacokinetic properties of the 
inorganic NP-loaded polymeric particles could be well controlled by polymer ligand 
on the particle surface. However, it is challenging to control the specific encapsulation 
efficiency of NPs per polymer particle which significantly restricts their clinical 
translation. 
 
Inorganic NP-loaded Polymeric micelles 
The micellization of polymers provides an efficient strategy for the encapsulation 
of inorganic NPs to form HPINs. Conventional polymeric micelles are obtained from 
the self-assembly of amphiphilic BCPs.27 The hydrophilic shell maintains the aqueous 
stability of polymeric micelles and protects the hydrophobic domains which act as a 
reservoir for loading inorganic NPs and therapeutic cargos. There are a variety of ways 
to encapsulate inorganic NPs into polymeric micelles, including co-precipitation, 





As the distribution of inorganic NPs in the polymeric micelles plays an important 
role in determining their properties, principles are developed to tune the spatial 
distribution of NPs basing on the interactions between NPs and polymer 
microstructures. By tuning the surface properties of NPs with capping agents, the 
interactions between ligand-polymer and ligand-surface could be well tailored to form 
various assembly structures. For instance, modifying NPs with polymer brushes favors 
the interaction of NPs with polymer host and reduces the attraction between NPs, which 
benefits for the uniform dispersion of NPs in polymer micelles. Similarly, parameters 
like the size of inorganic NPs (compared with the radius of gyration of the host 
polymer), the relative concentration of NPs and polymers, and the choice of solvent 
could also significantly influence the spatial distribution of NPs and the number of NPs 
encapsulated within each micelle.29-32 Park et al obtained three distinct structures by 
tuning the hydrophiphilic/hydrophobic balance of BCPs for assembly: (i) magneto-
polymersomes with densely packed magnetic NPs in the membrane; (ii) magneto-core-
shell assemblies with NPs radially arranged at the interface of the core and shell region; 
(iii) magneto-micelles with homogeneously incorporated NPs (Figure 1.5). The varied 
structure of assemblies was also realized by using different solvent conditions, which 







Figure 1.5. Fabrication of polymeric micelles loaded with inorganic NPs. Self-
assembly of NPs and BCPs into (I) magneto-core shell assemblies, (II) magneto-
micelles, and (III) magneto-polymersomes. Reproduced with permission from Ref. 
[30]. Copyright 2011 American Chemical Society. 
 
Inorganic NPs can also be loaded into polymeric micelles by in situ synthesis. This 
approach usually involves loading precursors into the micelle assembled from BCPs, 
followed by the reaction of the precursor to form NPs in the center.33 In this case, the 
size of NPs can be tuned by the length of the polymer brush. Moreover, in situ synthesis 
using polymeric micelles of conventional linear BCPs as nanoreactors can provide NPs 
with well controlled polymer layers. However, the stability of micellar aggregates is 
sensitive to temperature and solvent condition, which limits the types of inorganic NPs 






Polymer vesicles internally encapsulated with inorganic NPs 
Depending on the inherent curvature of the amphiphilic BCPs, their self-assembly 
in selective solvents also renders the formation of polymersomes, in which the 
hydrophobic block forms a vesicular shell, leaving the hydrophilic brush extends to 
both the interior and exterior sides of the vesicles. Typical strategies for assembly 
include emulsion-solvent evaporation, nanoprecipitation, dialysis, microfluidic 
fabrication, and thin film rehydration.1 In a thin film rehydration process, a film of 
BCPs is formed on the substrate and water is added to rehydrate the film with or without 
the assistance of sonication or heating. The polymer layers swell and form protrusions 
that detach from the surface of substrate and enclose to form water-soluble vesicles. A 
broad size distribution of vesicles is commonly observed due to the nonequilibrium 
nature of the vesicle formation process.34 When hydrophilic inorganic NPs are 
dispersed in water for film rehydration, this procedure generates polymeric vesicles 
with inorganic NPs trapped in the inner aqueous cavity. A relatively large amount of 
inorganic NPs could be loaded in an individual vesicle when concentrated NPs solution 
is used for rehydration.35 
 
Polymer vesicles embedded with inorganic NPs in the membrane 
Hydrophobic inorganic NPs can be encapsulated within the membranes of polymer 
vesicles to produce vesicular nanohybrids. The incorporation of NPs in the vesicular 
membrane originates from the co-assembly of a mixture of inorganic NPs and 
amphiphilic BCPs. IONPs and noble metal NPs with hydrophobic capping agents are 





embedded in the membrane via hydrophobic interactions, rather than covalent bonding 
with polymers. Generally, the thickness of polymersome membrane can be adjusted in 
the range of 10-50 nm, which largely defines the size of inorganic NPs that can be 
integrated in the membrane (usually less than 10 nm).37 When inorganic NPs with sizes 
comparable to the membrane thickness are used, the NPs would rather distribute at the 
periphery of the bilayer to decorate the hydrophobic/hydrophilic interface and form 
bilayer structures. As a result, oligo- or multiamellar vesicles or even onion-type 
vesicles are formed with NP bridging the adjacent bilayers.38 
The relationship between the NP-incorporation and the vesicle morphology has 
been broadly investigated. Park et al showed that the increase in size of inorganic NPs 
led to the increase in the yield of vesicles and the decrease in the vesicular size, as well 
as more ordered organization of NPs in the membrane. This NP size dependent 
morphology transition can be attributed to the entropic cost arises from incorporating 
large NPs into the polymer domain.39 By carefully tuning the NP size, inorganic NP-
bearing polymer vesicles could be fabricated with tailored size and properties for a 
variety of biomedical applications. 
 
Hybrid vesicles assembled from polymer-tethered inorganic NPs 
As mentioned above, the size and content of inorganic NPs that can be loaded in 
the hydrophobic domain of polymeric vesicles are often limited due to the possible NP 
integration-induced instability and morphological transition of vesicles. Unlike those 
structures, hybrid vesicles assembled from polymer-tethered inorganic NPs contain 





significantly enhances the stability and loading of inorganic components. Inspired by 
the assembly of amphiphilic molecules, colloidal amphiphiles was constructed for the 
fabrication of hybrid vesicles comprising closely packed inorganic NPs in the 
membrane of vesicles. Amphiphilic BCPs or a mixture of hydrophilic and hydrophobic 
homopolymer brushes are grafted on the surface of NPs to achieve amphiphilic nature, 




Figure 1.6. Assembly of polymer-tethered inorganic NPs into hybrid vesicles. (a) 
Scheme and SEM images of spherical and tubular vesicles assembled from PEO-b-PS 
tethered GNPs. Reproduced with permission from Ref. 42. Copyright 2012 American 
Chemical Society. (b) Scheme and SEM images of different structures via microfluidic 
self-assembly of amphiphilic PEO-b-PS tethered Au NRs in microfluidic flow-
focusing devices. Reproduced with permission from Ref. 41. Copyright 2013 WILEY-
VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
Assembly of amphiphilic NPs in selective solvents can be realized by dialysis, film 





example, a solution of polymer tethered inorganic NPs (in THF) together with two 
water streams are introduced in a microfluidic flow-focusing device (Figure 1.6b). The 
streams of two miscible fluids form a laminar flow and the diffusion of molecules along 
the transverse direction gradually changes the solvent quality for the hydrophobic 
blocks of BCP tethered on NPs, thus driving the association of colloidal amphiphiles 
to form different structures.42,43 The formation of assemblies with different 
morphologies (e.g., micelles, sheets, and giant vesicles) is determined by the 
hydrodynamics of flow and the characteristics (e.g., hydrophobic/hydrophilic balance) 
of colloidal building blocks. In recent years, this method is applicable for assembling 
NPs with a broad range of sizes (5-60 nm) and shapes (spherical NPs, NRs, 
nanoflowers, nanochains) into hybrid vesicles.44-47 Various factors (e.g., size and shape 
of inorganic NPs, the length of polymers, and the grafting density of polymers) are 
found to influence the vesicle formation and the morphology of vesicles significantly. 
For instance, the assembly of poly(ethyl oxide)-block-polystyrene (PEO-b-PS) grafted 
gold nanoparticles (GNPs) was found to depend on the hydrophobic/hydrophilic 
balance for various structures (e.g., hybrid vesicles, clusters, unimolecular micelles). 
The balance is determined by the ratio between the length of hydrophobic block in 
BCPs (R) and the relative size of GNPs (d).44 Spherical vesicles are formed when 
R/d<0.5. When R/d is close to 0.5, formation of one dimensional tubular structures is 
preferred. 
The co-assembly of polymer-tethered inorganic NPs with free polymer and/or 
other types of NPs leads to NPs-bearing vesicles with various morphologies and 





b-PS and free PEO-b-PS in selective solvent generated a series of hybrid vesicles with 
various shapes, including patchy vesicles with islands of NP membranes, shaped Janus 
vesicles with spherical/hemispherical/disk-like shapes, and heterogeneous vesicles 
with uniform distribution of NPs in the membranes.48 The formation of various 
patterned vesicles was attributed to the complex interaction between the dimension 
mismatch of building blocks, the entanglement of BCP chains, and the mobility of the 
NP amphiphiles. The co-assembly of GNPs tethered with PEO-b-PS, free PS-b-PAA 
and hydrophobic IONPs in selective solvents led to the formation of Janus vesicles 
where GNPs and IONPs are distributed in two distinct halves. Tuning the size and mass 
fraction of NPs could produce spherical and hemispherical Janus vesicles with distinct 
transverse relaxivity value and absorption in near infrared (NIR) range for further 
biomedical applications.50 
 
1.2.3 Applications of HPINs in biological imaging 
The incorporation of inorganic NPs into hybrid assemblies facilitates the imaging 
capability of the platform, as a result of their intrinsic properties and the coupling 
between adjacent subunits. The imaging capability provides HPINs with at least the 
following important functions. First, imaging of HPINs offers spatial and temporal 
information regarding the tumor angiogenesis and tumor microenvironment both in the 
primary tumor and in metastatic sites. This information is crucial for early diagnosis of 
tumor and/or for the selection and optimization of therapeutic strategies. Second, the 
imaging capability of HPINs can be used to characterize the biodistribution of NPs and 





guarantee the accumulation of sufficient NPs at tumor tissues. Third, imaging of HPINs 
makes possible to monitor the delivery dynamics of therapeutic agents, and predict the 
possible outcomes of therapy. Based on this information, therapy can be potentially 
optimized and personalized to achieve maximum antitumor efficiency. (Figure 1.7) 
 
 




As one of the most commonly used fluorescence imaging agents, quantum dots 





with size on the same order of or smaller than their exciton Bohr radius where the 
energy is quantized. The absorption of a photon with energy higher than the 
semiconductor band gap energy generates excitons and results in a broadband 
absorption spectrum of QDs for photons with short wavelengths. The subsequent 
recombination of an exciton leads to the emission of a photon in a narrow energy band. 
Due to the quantum confinement effect, QDs exhibit luminescence emission that is 
strongly dependent on their size. The emission of QDs shows unique features such as 
super-brightness, relatively narrow emission band (v.s. organic fluorophore), tunable 
emission wavelength and low photobleaching, which makes them appealing for non-
destructive bioimaging.51-53  
Despite their extraordinary optical properties, QDs are prone to surface oxidation 
and hence release toxic heavy metal ions to surrounding biological medium. Recent in 
vitro and in vivo studies showed that QDs are cytotoxic to various cell lines and 
tissues.54 The cytotoxicity of QDs is dependent on the dose and duration of exposure, 
as well as their physicochemical properties. Therefore, long-term safety concerns 
severely limit the in vitro and particularly in vivo applications of QDs. Insufficient 
fluorescence is another defect of conventional QDs-based bioimaging. Due to the 
surface defects in the crystal structure acting as temporary “traps” to prevent their 
radiative recombination, QDs may experience intermittent fluorescence and/or reduced 
overall quantum yield (QE) which is denoted as the ratio of emitted to absorbed photons. 
Coating the surface of QDs with an organic or inorganic shell can improve the 
fluorescence QE and stability against photobleaching, prevent the release of metal ions, 





However, the optical properties of QDs are highly sensitive to their local surroundings 
(i.e., the property of protective shell). The quantum efficiency of QDs is often 
drastically reduced when they are coated with inorganic layers such as silica.57 In order 
to solve these issues, assemblies of QDs in BCPs were prepared and demonstrated to 
improve the stability, while preserving the optical property of QDs.58,59 Nie et al. 
studied the application of CdSe-loaded polymer micelles for in vivo cancer targeting 
and imaging.55 Single tri-n-octylphosphine oxide (TOPO)-covered hydrophobic CdSe 
QDs were encapsulated in polymer micelles of ABC triblock copolymer of 
poly(butylacrylate)-b-poly(ethylacrylate)-b-poly(methacrylic acid)  (PBA-b-PEA-b-
PMAA) and stabilized by poly(ethylene glycol) (PEG) corona. The tight wrapping of 
QDs by the hydrophobic segments of BCPs prevents the fluorescence loss of QDs. 
Meanwhile, the optical properties of QDs were preserved in a broad range of pH (1 to 
14) and salt conditions (0.01 to 1 M), which significantly facilitates their applications 
in biological imaging and diagnosis. 
 
Multiphoton absorption induced emission (MAIE) imaging  
Multiphoton absorption induced emission (MAIE) imaging is an attractive optical 
imaging techniques for biological applications.60-63 The absorption of multiple photons 
occurs when the sum energy of a few photons (normally two or three low energy 
photons) matches the band gap and hence excites electrons at the ground state. As the 
probability of simultaneous absorption of two or more photons is extremely low, the 
MAIE only takes place at a high photon density of flux (e.g. the focus plane of pulsed 





technique, including: i) deeper penetration of living tissues and organs because of the 
excitation light in NIR range; ii) easier acquisition of 3D imaging with high spatial 
resolution; and iii) lower background noise. Metal and semiconducting NPs have been 
reported for their significantly higher multiphoton absorption cross-section (i.e. high 
brightness) than that of organic fluorophores, making them more promising agents for 
deep in vivo multiphoton imaging.63 
Ensembles of noble metal NPs show promising collective optical properties arising 
from the coupling between neighboring NPs. The plasmonic-enhanced multiphoton 
absorption results in a more intense MAIE signal than individual NPs, thus facilitating 
their application in bioimaging.64,65 Recently, Nie et al. demonstrated the utilization of 
HPINs for enhanced MAIE imaging of 4T1 cancer cells with the excitation of a NIR 
laser.66 It was found that in vitro MAIE signal gradually increased with increases in the 
aggregation number of NPs within cluster or vesicular assemblies of 20 nm GNPs, 
which significantly improved the imaging contrast after the assembly of GNPs. 
 
Dark Field Imaging 
Dark field imaging collects the light scattered by the sample to create an image in 
which the sample appears bright against a dark background. Metallic NPs can be used 
as non-bleaching labels for dark field imaging of biological samples because they can 
effectively scatter light over a narrow band of wavelengths. The scattering cross-
section of metallic NPs drops rapidly with a decrease in size and so does the imaging 
signal. Although large metallic NPs provide strong imaging signal, there are concerns 





translation.8 Assembling small metallic NPs into nanoscale hybrids that can be 
degraded to original small building blocks offers a strategy to potentially address this 
problem.67 As an example, Tam et al. assembled sub-5 nm GNPs into biodegradable 
polymer/NP clusters with controlled diameter in the range of ~50-100 nm with strong 
NIR absorption for imaging and therapeutic applications.68 The assemblies exhibited 
dark-field reflectance and hyperspectral imaging in a murine macrophage cell line. 
After remaining in the cells for 1 week, the large nanoclusters (~100 nm in diameter) 
dissociated into original GNPs (smaller than 5 nm in diameter), thus demonstrating the 
efficient body clearance of the NPs.  
 
Photothermal (PT) and Photoacoustic (PA) Imaging 
PT imaging is based on temperature–induced variation in the refractive index of 
tissues and organs to transform invisible NPs into visible thermal field image upon laser 
irradiation. In contrast to PT imaging, PA imaging detects and transforms the 
propagation of wideband ultrasound waves induced by PT heating in tissue into an 
image. In PA imaging, the tissue absorbs light irradiated by a laser beam and partially 
or completely converts the absorbed photon energy to heat. This non-invasive imaging 
technique seamlessly combines the merits of both ultrasonic technique and optical 
imaging. Compared with conventional optical imaging, this technique shows stronger 
optical absorption contrast of biological tissue, higher ultrasonic spatial resolution, and 
deeper penetration in biological tissues beyond the optical diffusion limit. 
To achieve enhanced and precise visualization, exogenous contrast agents are 





NPs)69-71 and polymeric NPs (e.g, polypyrrole NPs)72,73 have been utilized as PT 
conversion agents. Among the different PT conversion agents, gold nanostructures are 
particularly attractive due to their absorption of light, high thermal conductivity, and 
superior stability and biocompatibility.74,75 However, the absorption peak of spherical 
GNPs is in the wavelength range of 520-580 nm, which is not ideal for in vivo PT 
and/or PA imaging. Compared with visible light, NIR laser exhibits a minimal 
absorption of light by tissues and the resultant deeper tissue penetration. The assembly 
of GNPs can tune the plasmon coupling between NPs and shift the absorption peak of 
a collection of GNPs to the NIR region, which could significantly enhance the 
biological performance of NPs than their individuals without strong NIR absorption. 
Among various assembly structures of GNPs, vesicles have attracted considerable 
interest due to their effective loading of both hydrophilic and hydrophobic agents for 
tumor imaging and therapy. To modulate the optical property and therapeutics loading 
of the HPINs, Nie et al. designed vesicular assemblies with a single layer of GNPs 
tethered with amphiphilic PS-b-PEO in the membrane.44,66,76,77 The strong plasmonic 
coupling between closely-packed GNPs within membranes led to a strong absorption 
of the assemblies in the NIR window. The hybrid vesicles were demonstrated for 
effective in vivo multi-modality imaging (i.e., PT imaging, PA imaging, and 
fluorescence imaging) of subcutaneous MDA-MB-435 breast cancer xenografts in 
athymic nude mice.76 The organization of GNPs in vesicular membranes was found to 
be crucial to their performance in PT and/or PA imaging, as a result of the optimization 
of light absorption in the NIR window. More recently, Nie’s group further reported the 





form vesicular containers (Figure 1.8).47 The linear ordering of NPs within vesicular 
membranes resulted in a strong absorption of assemblies at NIR wavelengths (ca.760 
nm). This subtle change in the organization of NPs led to a nearly ten-fold enhancement 




Figure 1.8. (a-c) Schematic illustration of the self-assembly of BCP tethered GNPs 
(BCP-GNPs) into chain vesicles and non-chain vesicles and (d) the enhanced PA 
imaging with chain vesicles. In vivo 2D PA imaging of mouse tissue before and after 
the injection of chain vesicles (a, b) and none chain vesicle (c, d). Two types of vesicles 
containing the same amount of gold materials (50 µg) were subcutaneously injected 
into the flank of nude mice and was irradiated with a pulsed NIR laser (780 nm, 60 
mW/cm2) for equal amount of time. Reproduced with permission from Ref. 45. 
Copyright 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 





Magnetic Resonance imaging (MRI) is a non-invasive imaging technique with a 
spatial resolution on the order of tens of micrometers. This technique has been widely 
used in cancer imaging and diagnosis, as it offers anatomic and functional information, 
such as tumor volume and angiogenetic status. Typically, hydrogen protons will align 
and process around an applied magnetic field, when a transverse radio-frequency pulse 
is applied, these protons are disturbed from the magnetic field and return to their 
original state, which is referred as relaxation phenomenon. The MRI is generated by 
monitoring two independent processes, i.e. longitudinal relaxation (T1-recovery) and 
transverse relaxation (T2-decay). The proton density, chemical and physical nature of 
the tissues result in the image contrast. Contrast agents are usually required to provide 
high resolution and accuracy for effective cancer diagnosis and assessment in MRI. 
The shortening of both the longitudinal and transverse relaxation of surrounding 
protons can be achieved by magnetic NPs (MNPs). The T1 shortening process is based 
on the close interaction between protons and T1 agents while the T2 shortening arises 
from the large susceptibility difference between MNPs and surrounding medium. 
MNPs such as superparamagnetic iron oxide NPs (SPIONs) are generally used as 
negative T2 contrast agents in MRI as a result of more significant T2 effect.
78,79 MNPs 
synthesized by high temperature decomposition of organic precursors often show 
superior magnetic properties for efficient MRI. However, the hydrophobic nature of 
their surfaces makes them not suitable for direct use in biological conditions. Polymers 
are frequently assembled with MNPs to increase the stability and biocompatibility of 
the MNPs.80 In addition, compared with single NP-based contrast agent systems, 





largely due to more uniform magnetization and numerous MNP/water molecule 
interactions.81,82 
The clustering of MNPs and accessibility of water molecules to MNPs are crucial 
factors in determining the relaxivity rates of MRI contrast agents. Therefore, the size, 
morphology and NP arrangement of polymer/MNP assemblies can significantly 
influence the magnetic relaxation of the assemblies and hence their performance in 
MRI. The enhancement in the relaxivity of HPINs assemblies has been observed in 
MNP-loaded micelles and solid NPs, as well as polymersomes embedded (or loaded) 
with MNPs in the membranes (or within the hollow cavity).83,84 However, a lack of 
specific control of the MNPs density in the assemblies hinders further applications of 
the HPINs in biological imaging. 
 
1.2.4 Applications of HPINs in tumor therapy 
The utilization of hybrid assemblies for cancer therapy originates from at least the 
following merits of the platform. First, the superior imaging capability enabled by 
inorganic NPs offers an attractive way to monitor microenvironment changes 
associated with cancer at molecular level.85 Second, the integration of imaging and 
therapy in one system (so-called “theranostics”) allows one to simultaneously track the 
delivery of both nanocarriers and therapeutic agents to tumor sites, to determine the 
angiogenic activity of tumor, as well as to evaluate the outcome of cancer therapies. 
Third, the activation of payload release from hybrid assemblies by light or magnetic 
field can reduce non-specificity and improve the efficacy of systematic drug delivery.36 





photodynamic-chemotherapy, etc.) can further maximize the therapeutic outcomes by 
reducing drug resistance or promoting possible synergetic effect between multiple 
therapies (Figure 1.9).86 
 
 




Hyperthermia therapy utilizes localized heating to damage tumor cells or make 
tumor cells more sensitive to therapeutic agents, while minimizing damage on healthy 





result of sparse vascular structures of tumor. While conventional methods (e.g., 
ultrasound and microwaves) can efficiently deliver heat to tumors, a major concern for 
these approaches is the exposure of a large volume of normal tissues to hyperthermic 
temperature. HPINs can provide the specificity required for thermal ablation of tumors. 
In this case, heating can be confined in the vicinity of hybrid assemblies which are 
preferentially accumulated in the tumor tissue, if the volume of treatment and exposure 
time of light are carefully controlled. Various magnetic, metallic and semiconductor 
NPs capable of generating heat have been integrated in the hybrid assemblies as 
hyperthermia agents for this purpose.87,88 The unique imaging capability of these NPs 
can guide the tumor-targeted delivery of the NPs, thus further improving the likelihood 
of successful treatment of cancer. 
MNPs can generate heat efficiently when exposed to an external alternating 
magnetic field (AMF).89 The efficiency of heating is proportional to the magnetization 
of NPs, as well as the amplitude and frequency of applied AMF. Therefore, MNPs have 
been widely explored as efficient hyperthermia agents in HPINs for simultaneous 
cancer imaging and therapy.90-93 Magnetic hyperthermia is capable of eliminating 
tumors that are resided deeply inside the biological system, as the penetrating depth of 
magnetic field is not limited. This technique is non-invasive and does not cause any 
adverse effect on biological tissues. Moreover, the magnetization and movement of 
MNPs under magnetic field can be used to locally concentrate NPs at a desired site of 
tissues to achieve specific targeting. 
The assembly of many MNPs within polymers can effectively maintain or increase 





manipulation. Hyeon et al. reported the assembly of multiple ferrimagnetic Fe3O4 
nanocubes in polymeric shell of chitosan oligosaccharide for magnetically modulated 
cancer hyperthermia.94 In this work, L-3,4-dihydroxyphenylalanine (DOPA)-
conjugated chitosan was used to assemble 30-nm-sized nanocubes through the strong 
interaction between catechol groups of DOPA and iron oxide surfaces. The hybrid 
assemblies locally accumulated in human lung carcinoma A549 cells under a magnetic 
field, thanks to the increased magnetic moments of multiple nanocubes. The assembly 
platform exhibited significantly higher hyperthermal efficiency than commercial 
superparamagnetic Feridex NPs, demonstrating the promising prospect of HPINs in 
hyperthermia tumor therapy. 
Photothermal therapy (PTT) is another minimally invasive therapeutic technique 
that utilizes light and PT agents to produce localized heating for the thermal ablation 
of cancer cells.95 In this method, localized heating of tumor tissues can be achieved by 
controlling the regional delivery of PT agents as well as the direction and focus of 
incident radiation, thus greatly improving the efficiency and specificity of 
hyperthermia therapy. An ideal PT agent should have the following features: 1) strong 
absorption in the NIR region ideally between 700 and 1300 nm; 2) high PT conversion 
efficiency and good thermal conductivity; 3) biocompatibility and no severe toxicity; 
and 4) potential of being eliminated from the body. 
The assembly of NIR-absorbing GNPs with polymers can improve the 
biocompatibility, PT stability and reduce the possible cytotoxicity of the individual 
NPs.96-100 As one of the most commonly used photothermal agents, gold nanorods 





which is known to be toxic to cells and tissues. However, removal of CTAB causes the 
aggregation of GNRs in buffer or body fluids. In addition, CTAB-stabilized GNRs 
were rapidly excreted or accumulated in the liver, resulting in reduced PT efficiency at 
the tumor site. In contrast, polyelectrolyte-coated GNRs were fabricated and showed 
excellent long-term optical stability in various biological media, thus facilitating their 
PT ablation of PC3-PSMA human prostate cancer cells.98 
Most NIR-absorbing GNPs such as Au nanoshells usually have a diameter over 40 
nm (sometimes above 100 nm). These NPs with relatively large size often preferentially 
accumulate in organs such as liver, spleen, and kidneys.101 It poses a great challenge to 
eliminate these NPs from the body. In contrast, small NPs (e.g., NPs with diameter 
below ~8 nm) are more compatible with renal clearance, but at the expense of 
insufficient absorption in the NIR region, which is required to achieve desired 
penetration depth in tissue, and to avoid unnecessary damage to healthy tissue.  
The assembly of NPs offers an elegant strategy to turn GNPs into strong NIR 
photoabsorbers for effective imaging and therapy of cancer.44,66,102,103 Nie et al. 
demonstrated the assembly of BCP-tethered GNPs into hollow nanovesicles with 
strong NIR absorbance for multimodality imaging–guided PTT of tumors.76,77 The 
absorption peak of the hybrid vesicles can be turned to the NIR range by controlling 
the size of spherical GNPs, the length and type of BCP tethers. When a BCP of PS-b-
PCL was used, the strong NIR absorption of vesicular assemblies (~650-800 nm) 
enables the use of NIR irradiation to excite the hybrid structures to produce heat for PT 





the irradiation the hybrid vesicles dissociate into individual GNPs which facilitates 
their rapid clearance from the body. 
 
 
Figure 1.10. (a) Schematic illustration of the self-assembly of biodegradable gold 
vesicles (BGVs) composed of PEG-b-PCL-tethered GNPs for superior PA imaging and 
PTT with improved clearance. (b) Heat curves of tumors upon laser irradiation (808 
nm laser) as a function of irradiation time. (c) PA signals of BGVs and Au NRs as a 
function of optical density. (d) Tumor growth curves of different groups of MDA-MB-
435 tumor-bearing mice after treatment. (d) Pharmacokinetics of BGVs in different 
organs at 1, 2, and 8 days after the intratumoral injection of BGVs. Reproduced with 
permission from Ref. 75. Copyright 2013 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. 
 
Nanomaterials-based hypothermia therapy is quite straightforward and easy to 
implement. The efficacy of the treatment is largely dependent on the accumulation of 
these NPs at tumor sites and the accessibility of light to those areas. The confinement 





cause incomplete ablation of tumor, due to the non-uniform distribution of NPs in 
tumor areas. Therefore, hypothermia therapy is often used in combination with other 
therapeutic strategies (e.g., chemotherapy or photodynamic therapy). 
 
Drug Delivery and Combination Therapy 
Systemic drug delivery often fails to deliver exact dosage of therapeutic agents 
specifically to tumor sites at the desired time to suppress cancer metastases.104,105 
Severe side effects may arise from the non-specificity and toxicity of drugs, which can 
make patients extremely weak and even result in death. Moreover, due to the poor 
efficacy of non-specific chemotherapy, nearly 50% of all cancer patients will develop 
drug resistance over times for most of anticancer drugs. For this reason, chemotherapy 
combined with other strategies (e.g., radiation and PT ablation, photodynamic therapy) 
is considered as the standard of care for cancer patients particularly at the later stages. 
HPINs may provide a unique platform for safer and more efficient delivery of 
therapeutic agents for combination therapy. 
 
Image-guided drug delivery 
HPINs have been widely explored for image-guided drug delivery. The imaging 
capability of inorganic NPs can help identify tumor sites and optimize the 
pharmacokinetics and biodistribution of drug nanocarriers by tracking their location in 
cells or tissues. It also makes it possible to trace the in vivo release kinetics of 
therapeutic agents in real time. Duan et al. developed SERS-active hybrid vesicles for 





vesicles with hollow cavity were assembled from GNPs tethered with a mixture of 
hydrophilic PEG and hydrophobic copolymer (PMMAVP) of MMA and 4-
vinylpyridine (4VP) and subsequently conjugated with a monoclonal antibody of HER2 
protein as a cancer biomarker. Raman dye BGLA was also immobilized on the surface 
of GNP building blocks before assembly. The bioconjugated doxorubicin (Dox) loaded 
vesicles can specifically target HER2-positive SKBR-3 breast cancer cells, dissociate 
and release the payloads in acidic intracellular compartments, due to hydrophobic-to-
hydrophilic transition of the hydrophobic PMMAVP in acidic environment. The 
disassembly of vesicles was associated with dramatic decrease in scattering properties 
and SERS signals of Raman reporters due to the variation in the plasmonic coupling 
between GNPs. Upon dissociation of Au vesicles, the SERS intensity of Au vesicles 
dropped by 34-fold at 1615 cm-1 and became very weak, which makes the vesicles 
traceable by Raman spectroscopy. Thus, the cargo release from the vesicles can be 
uniquely monitored by dark-field imaging and Raman spectroscopy, which can be used 







Figure 1.11. (a) Schematic illustration of a GNP coated with Raman reporter BGLA 
and a mixture of hydrophilic PEG and pH-sensitive hydrophobic PMMAVP polymers 
and a pH-sensitive drug-loaded plasmonic vesicle surface-immobilized with HER2 
antibody for cancer cell targeting. (b) The cellular binding, uptake, and intraorganelle 
disruption of the SERS-encoded plasmonic vesicles. (c) Raman spectra of the vesicle 
at pH 7.4 (red) and pH 5.0 (blue). (d) Representative Raman spectra of SKBR-3 cells 
labeled with targeted vesicles after 30 min incubation (black line) and the post-
incubation spectra of the cells at 60 min (red line) and 90 min (blue line). Reproduced 






Internal Stimuli-triggered Release of Therapeutic Agents 
Conventional drug delivery nanocarriers have a limited ability to maintain an 
effective drug concentration at a desired location and specific time window, due to 
passive release of payloads. On-demand drug release using stimuli-responsive systems 
has the potential to achieve spatiotemporal control over an acute level of drug 
concentration. The microenvironment at tumor sites is slightly different from that at 
normal tissue, such as lower pH value, different reduction potential, and overexpression 
of some enzymes. These abnormal changes can be used as internal stimuli for 







Figure 1.12. Schematic Illustrations of (a) the synthesis of nanoceria-doped SPNs and 
the self-regulated photodynamic properties of SPNs at physiologically neutral and 
pathologically acidic conditions and (b) the comparison between self-regulated and 
conventional PDT-mediated by nanoceria-doped SPNs and nondoped SPNs, 
respectively. Reproduced with permission from Ref. 106 Copyright 2017 American 
Chemical Society. 
 
By combining the properties of both polymers and inorganic NPs, HPINs have 
shown great potential in the design and fabrication of stimuli-responsive delivery 
vehicles. Pu et al. developed a nanoceria-doped semiconducting polymer NPs (SPNs) 
to regulate photodynamic cancer therapy in various pH values (Figure 1.12).108 The 
SPNs showed strong absorption in the NIR region and served as both fluorescence 
agents and photosensitizers while nanoceria can act as reactive oxygen species (ROS) 
scavenger in tumor acidic environment and transfer to converter at neutral pH. In 
neutral environment, nanoceria can convert ROS into oxygen in a recyclable way due 
to the presence of the Ce3+ (reduced) and Ce4+ (oxidized) states on their surface; 
however, they become the ROS converter to transform O2
•− to H2O2 under acidic 
conditions. The pH-dependent switch of photodynamic properties of SPNs not only 
amplifies phototherapy in the acidic microenvironment of tumor but also potentially 
reduces the side effect in normal tissues. 
 





External stimuli such as light, ultrasound, and magnetic field can be used to 
activate the release of drug payload from nanocarriers for on-demand therapy. The use 
of external stimuli offers good flexibility in switching on and off the drug release and 
superior precision in the control over time, space, and dose of drug release. Compared 
with others, light is the most frequently used stimulus, largely due to the portability of 
light sources and ease in application. The light responsiveness of hybrid assemblies can 
be originated from the responsiveness of polymers, or the PT effect of inorganic 
components, or the combination of both. 
PT heating of loaded inorganic NPs can be used to achieve NIR-responsiveness 
of hybrid assemblies for deep tissue PTT and controlled drug release. In this case, the 
design of hybrid assemblies requires either the phase-transition of the polymer matrix, 
or relatively weak association of polymers (and NPs), or the possession of vesicular 
membranes which tend to break upon interference. Thin polymer (or composite) 
membranes tend to break up in response to mechanical force or variation in osmotic 
pressure or temperature. When NPs are loaded in the hollow cavities, immobilized on 
the surface, or embedded within the membranes of vesicles or capsules, the localized 
heating induced by light can break up the thin membrane and trigger the delivery of 
payload on demand.50,76,77  
One typical example of NIR-responsive HPINs is the recently emerged new class 
of plasmonic vesicles comprising a single layer of closely-packed GNPs (or GNRs) in 
the membrane.43,50,76,109 Upon laser irradiation, the localized heating of NPs within 
assemblies dissociated the assembled hybrids to release loaded active compounds, as a 





the shape change of NPs. Vesicular assemblies of GNRs tethered with amphiphilic 
BCPs of PS-b-PEO could be fabricated by microfluidic method, and the NIR-light 
triggered release of payloads was evaluated for drug release.43 Upon the irradiation of 
NIR pulsed laser beam (60 mW, 808 nm), the membrane of vesicular hybrids was 
disturbed to release encapsulated model drug, rhodamine B. A close inspection 
indicated that GNRs within membranes were melted and deformed to spherical GNPs, 
as a result of intensive localized heating. A comparison between systems with laser on 




Figure 1.13. a) NIR-triggered release using giant vesicles. The photothermally induced 
shape deformation of GNRs to spherical GNPs creates extra spacing between GNPs for 
the release of encapsulated molecules. b) SEM images of giant vesicles before and after 
exposed to NIR laser. The GNRs in the vesicles deformed to spherical GNPs upon 





Rhodamine B (excitation at 540 nm) with a 5 min interval under the irradiation of 800 
nm laser. d) The release profiles of Rhodamin B giant vesicles with laser on (○) and 
off (□). Reproduced with permission from Ref. 41. Copyright 2013 WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim. 
 
1.3 Scope of the dissertation 
As discussed in previous sections, the assembly of inorganic NPs into HPINs offers 
a variety of desired properties for biological imaging and therapy. I have chosen 
colloidal amphiphiles as building blocks for fabricating functional HPINs, because of 
i) their intrinsic and collective physiochemical properties arising after the assembly 
and ii) their capacity to mimic molecular self-assembly to form various assembly 
structures. The objective of this dissertation is to study the self-assembly of inorganic 
NPs into HPINs, to tailor the properties of the assemblies and to improve the 














Chapter 2: Plasmonic vesicles-based signal amplification for 
ultrasensitive colorimetric assay of disease biomarkers 
 
Overview. In this work, we demonstrate an enzyme-free signal amplification technique, 
based on gold vesicles encapsulated with Pd−Ir nanoparticles as peroxidase mimics, 
for colorimetric assay of disease biomarkers with significantly enhanced sensitivity. 
This technique overcomes the intrinsic limitations of enzymes, thanks to the superior 
catalytic efficiency of peroxidase mimics and the efficient loading and release of these 
mimics. Using human prostate surface antigen as a model biomarker, we demonstrated 
that the enzyme-free assay could reach a limit of detection at the femtogram/mL level, 
which is over 103-fold lower than that of conventional enzyme-based assay when the 
same antibodies and similar procedures were used. 
 
This chapter is adapted from the manuscript published in the following article: Ye, H.†, 
Yang, K.†, Tao, J., Liu, Y., Zhang, Q., Habibi, S., Nie, Z.# and Xia X.#, An Enzyme-
Free Signal Amplification Technique for Ultrasensitive Colorimetric Assay of Disease 
Biomarkers, ACS Nano, 2017, 11 (2), 2052–2059. My works include the design of 
nanoassemblies, encapsulation and release of Pd−Ir nanoparticles and their catalytic 
efficiency after the release. († Equal contribution) 
 
2.1 Introduction 
Simple and affordable technologies for detection of disease biomarkers are 
essential to the improvement of standard of living, especially for resource-constrained 
areas or countries. Enzyme-based colorimetric assays (e.g., enzyme-linked 





recognized as such kind of technology because they can be performed by less-trained 
personnel with an inexpensive spectrophotometer, ordinary light microscope, or even 
naked eyes.110-112 Nevertheless, the major drawback for these colorimetric assays is the 
relatively low detection sensitivity compared to other technologies such as those based 
on fluorescence and plasmonics.113-115 
In conventional colorimetric assays, the detectable color signal is generated from 
enzymes (in many cases, horseradish peroxidase, HRP) which are conjugated to 
antibodies and specifically convert substrates to colored molecules. Therefore, their 
detection sensitivity is largely determined by the performance of enzymes. Accordingly, 
a general strategy for enhancing the sensitivity is to amplify color signal by assembling 
as many enzyme molecules as possible on certain carriers (e.g., avidin, polymers, and 
nanoparticles).116-122 For example, Merkoci et al. conjugated HRPs to gold 
nanoparticles (GNPs) as carriers and applied these conjugates as labels to ELISA of 
breast cancer biomarker, of which detection sensitivity was several times higher than 
conventional ELISA using HRP as label.120 Qian et al. further increased HRP loading 
amount by employing a combination of GNPs and grapheme oxide sheets as carriers, 
achieving a 64-fold improvement of sensitivity.121 Despite these demonstrations, the 
detection sensitivity is ultimately limited by the catalytic efficiency of enzymes and the 
loading amount of enzymes on a carrier. 
This chapter describes an enzyme-free signal amplification technique to break the 
intrinsic limitations of enzymes, achieving substantially enhanced detection sensitivity. 
In this technique, sub-10 nm Pd-Ir nanoparticles (NPs) encapsulated gold vesicles 





study, we used ELISA as a model platform to demonstrate the enzyme-free technique, 
because ELISA has been the gold standard for detection and quantification of protein 
biomarkers for decades. As shown in Figure 2.1, at elevated temperature, gold vesicles 
(GVs) captured by analytes liberate thousands of individual Pd-Ir NPs because of the 
heat-induced breakup of the GV membrane.44,76,77 The released Pd-Ir NPs act as 
peroxidase mimics and generate intense color signal by catalyzing the oxidation of 
3,3’,5,5’-tetramethylbenzidine (TMB, a classic HRP substrate) by H2O2.
123 It should 
be pointed out that we have recently demonstrated the peroxidase-like property of Pd-
Ir NPs and controlled release of GVs, respectively. However, to date, there has been no 
report yet on the development of a signal amplification platform based on the 
combination of these two systems. The ultralow detection limit of this enzyme-free 
ELISA arises from the following distinctive features of the amplification technique: (i) 
Pd-Ir NPs as enzyme mimics possess much higher catalytic efficiency than natural 
enzymes, providing enhanced color signal; (ii) the loading capacity of enzyme mimics 
is maximized by taking advantage of the large interior 3D space of the GVs as 
carriers;124,125 in contrast, the loading of enzymes on carriers in current designs of 
ELISA is limited by the surface area that allows for the conjugation of enzymes; (iii) 
the loading of label-free enzyme mimics of Pd-Ir NPs in the pocket of GVs avoids the 
loss of catalytic efficiency caused by chemical conjugation; (iv) Pd-Ir NPs could 
disperse in catalytic reaction solution upon release, making them more active than 







Figure 2.1. Schematic illustration of utilizing Pd-Ir NPs@GVs based ELISA for 
detection of disease biomarkers. The Pd-Ir NPs released from captured GVs act as 




Sodium hexachloroiridate(III) hydrate (Na3IrCl6·xH2O, MW=473.9), sodium 
tetrachloropalladate(II) (Na2PdCl4, 98%), gold(III) chloride trihydrate (HAuCl4·3H2O, 
≥ 99.9%), potassium bromide (KBr, ≥ 99%), L-ascorbic acid (AA, ≥ 99%), 
poly(vinylpyrrolidone) (PVP, MW ≈ 55 000), 3,3’,5,5’-tetramethylbenzidine (TMB, > 
99%), hydrogen peroxide solution (30 wt % in H2O), acetic acid (HOAc, ≥ 99.7%), 
sodium acetate (NaOAc, ≥ 99%), human prostate surface antigen (PSA, ≥ 99%), Tween 
20, bovine serum albumin (BSA, ≥ 98%), sodium chloride (NaCl, ≥ 99.5%), potassium 





Ethyl-N’-(3-(dimethylamino)-propyl)carbodiimide hydrochloride (EDC, ≥ 99%), 
sodium phosphate dibasic (Na2HPO4, ≥ 99%), potassium phosphate monobasic 
(KH2PO4, ≥ 99%), tris base ( ≥ 99.9%), sodium citrate, dimethylformamide (DMF), 
tetrahydrofuran (THF), sodium azide (NaN3, ≥ 99.5%), and sulfuric acid (H2SO4, 95-
98%) were all obtained from Sigma-Aldrich. Ethylene glycol (EG) was obtained from 
J. T. Baker. Mouse anti-PSA monoclonal antibody (mouse anti-PSA mAb) and rabbit 
anti-PSA polyclonal antibody (rabbit anti-PSA pAb) were obtained from Abcam plc. 
Goat antimouse IgG and HRP-goat antimouse IgG conjugate were obtained from 
Thermo Fisher Scientific, Inc. 96-well microtiter plates (polystyrene, clear, flat bottom) 
was obtained from Corning Inc. All aqueous solutions were prepared using deionized 
(DI) water with a resistivity of 18.0 M Ω·cm. 
 
2.2.2 Preparation of 5.6 nm Pd truncated octahedra as seeds 
In a typical synthesis, 30 mL of an EG solution containing 600 mg of PVP was 
hosted in a glass vial and preheated to 160 ° C in an oil bath under magnetic stirring 
for 10 min. Then, 15 mL of an EG solution containing 240 mg of Na2PdCl4 was quickly 
injected into the reaction solution using a pipet. The reaction was allowed to continue 
for 3 h. After being washed with acetone once and ethanol twice via centrifugation, the 
final product was redispersed in 10 mL of EG for future use. The concentration of Pd 
element in the final product was determined to be 7.5 mg/mL by ICP-OES, which could 
be converted to a particle concentration of ∼ 5×1015 particles/mL (assuming that the 






2.2.3 Preparation of Pd-Ir core-shell nanoparticles (Pd-Ir NPs) 
Pd-Ir NPs were prepared by coating a monolayer of Ir on Pd seeds according to 
our previously published procedure with some modifications.20 In a standard 
procedure, 100 mg of PVP and 60 mg of AA were mixed with the 10 mL Pd seeds in 
EG and were hosted in a 50 mL three-neck fl ask. The mixture was preheated to 200 ° 
C in an oil bath under magnetic stirring for 10 min. Then, 8.0 mL of Na3IrCl6·xH2O 
solution (7.0 mg/mL, in EG) was injected to the fl ask at a rate of 1.5 mL/h using a 
syringe pump. The reaction was allowed to proceed for an additional 10 min after the 
Na3IrCl6·xH2O precursor had been completed injected. The products (i.e., Pd-Ir NPs) 
were collected by centrifugation, washed once with acetone, two times with water, and 
finally redispersed in 1 mL of DI water for future use. Particle concentration for the 
suspension of Pd-Ir NPs was estimated to be 4.5 × 1016 by ICP-OES. 
 
2.2.4 Evaluation of peroxidase-like activity 
Peroxidase-like activity was measured by the steady-state kinetic assays.126 All 
assays were carried out at room temperature in 1.0-mL cuvettes (path length, l = 1.0 
cm), with 0.2 M NaOAc/HOAc solution, pH 4.0 being used as the reaction buffer. After 
addition of TMB and H2O2 in the buffer system containing nanoparticles as peroxidase 
mimics, the absorbance of the reaction solution at 653 nm of each sample was 
immediately measured as a function of time with interval of 6s using a 
spectrophotometer for 3 min. These “Absorbance vs Time” plots were then used to 
obtain the slope at the initial point (Slope Initial) of each reaction by conducting the 





(ν) was calculated by SlopeInitial /(εTMB-653nm × l), where εTMB-653nm is the molar 
extinction coefficient of TMB at 653 nm that equals 3.9 × 104M−1·cm−1. The plots of ν 
against TMB concentrations ([S]) were fitted using nonlinear regression of the 
Michaelis − Menten equation. The apparent kinetic parameters K m and V max were 
obtained from the double reciprocal plot (or Lineweaver − Burk plot) that was 
generated from the Michaelis − Menten equation ν = Vmax × [S]/(Km + [S]),47 where 
Vmax is the maximal reaction velocity and Km is the Michaelis constant. Kcat was derived 
from Kcat = Vmax / [E], where [E] represents the particle concentration of peroxidase 
mimics. 
 
2.2.5 Synthesis of amphiphilic block copolymers and gold nanoparticles 
Amphiphilic BCPs of poly(ethylene oxide)-b-polystyrene and poly(acrylic acid)-
b-polystyrene terminated with a thiol group at polystyrene end (PEO-b-PS-SH and 
PAA-b-PS-SH) were synthesized following the reversible addition fragmentation chain 
transfer (RAFT) polymerization procedures reported previously.66 The BCPs samples 
were designed with similar polystyrene (PS) lengths (PEO45-b-PS260-SH and PAA23-b-
PS250-SH) as verified by proton nuclear magnetic resonance (
1H NMR).  
GNPs with diameters of 33.0 ± 4.7 nm were prepared by sodium citrate reduction 
method.127 Briefly, a 10 mg of HAuCl4 was dissolved in 500 mL H2O and heated to 
boiling under stirring. A 3 mL of sodium citrate (1 wt %) solution was then quickly 
injected. The reaction mixture was refluxed for 30 min and then used as seeds for 
further growth of GNPs in the presence of sodium citrate at 80 ° C. The resultant 33.0 






2.2.6 Preparation of gold vesicles (GVs) and Pd-Ir NPs@GVs 
GVs and Pd-Ir NPs@GVs were prepared by assembling BCP-tethered GNPs in 
the presence of DI water or aqueous suspension of Pd-Ir NPs, respectively, according 
to our previously reported procedure with minor modifications.44 
The surface of GNPs was modified with BCPs using the ligand exchange method. 
A 5 mg BCPs of PEO45-b-PS260-SH and PAA23-b-PS250-SH with a molar ratio of 
20:1 were dissolved in 10 mL DMF. Then, a concentrated solution of GNPs (∼2 mg/mL) 
was slowly added into the BCP solution under vigorous shaking. The mixture was 
subsequently sonicated for 1 h to avoid the aggregation of GNPs and was then kept 
static without stirring overnight. The BCP-tethered GNPs were purified by removing 
free polymers through centrifugation (6-8 times) and were finally redispersed in THF 
at a concentration of ∼ 0.05 mg/mL. 
Self-assembly of BCP-tethered GNPs was conducted by the film rehydration 
method as reported previously.37 Briefly, a solution of BCP-modified GNPs in THF 
was first dried under nitrogen flow to form a thin film on a glass substrate, followed by 
rehydration in DI water (for pristine GVs) or an aqueous suspension of Pd-Ir NPs at 
4.5 × 1016 particles/mL (for Pd-Ir NPs@GVs) with sonication for 1 min. The resultant 
GVs and Pd-Ir NPs@GVs were collected by centrifugation (5000 rpm, 5 min), washed 






2.2.7 Preparation of Pd-Ir NPs@GVs-goat antimouse IgG conjugates 
Antimouse IgG was conjugated to Pd-Ir NPs@GVs using EDC and NHS as 
coupling agents (Figure 2.2).128 In brief, 50 μL of Pd-Ir NPs@GVs (∼ 0.5 mg/mL in 
terms of Au element, in DI water) was added to a 450 μL of 10 mM phosphate buffered 
saline (PBS, pH 7.4) buffer at room temperature under stirring. Then, 5 μL of EDC (25 
mM, in DI water) and 5 μL of NHS (50 mM, in DI water) were added. After 15 min, 
the particles were washed with DI water twice and redispersed in 50 μL PBS. 
Subsequently, 50 μL of goat antimouse IgG (2 mg/mL, in PBS) was added to the 
particle suspension. After incubation at room temperature for 30 min, the reaction 
solution was put in a refrigerator overnight at 4 ° C. Then, 100 μL of blocking solution 
(5% BSA in PBS) was added to the reaction solution. After 2 h, the final products were 
collected by centrifugation, washed twice with PBS, and redispersed in 50 μL of PBS 
containing 1% BSA and 0.05% NaN3 for future use. 
 
 
Figure 2.2 Schematic illustration showing the procedure for conjugation of antibodies 






2.2.8 Pd-Ir NPs@GVs-Based ELISA of PSA 
First, 96-well microtiter plates were coated with rabbit anti-PSA pAb (100 μL per 
well, 5 μg/mL in carbonate/bicarbonate buffer pH9.6) at 4 ° C overnight. After washing 
the plates three times with washing buffer (10 mM PBS pH 7.4 containing 0.5% tween 
20, PBST), the plates were blocked with 200 μL blocking buffer (3% BSA in PBST) 
for 2 h at room temperature. The plates were then washed three times with washing 
buffer, followed by the addition of 100 μL PSA standards or human plasma sample in 
dilution buffer (1% BSA in PBST). Note that plasma was prediluted 2 folds by dilution 
buffer prior to spiking of PSA and detection. After shaking at room temperature for 2 
h, the plates were washed three times with washing buffer, and 100 μL mouse anti-PSA 
mAb (2 μg/mL, in dilution buffer) was added. After 1 h shake at room temperature, the 
plates were washed three times, and 100 μL Pd-Ir NPs@GVs-goat antimouse IgG 
conjugates (1:2000, in dilution buffer) was added, followed by 30 min shake at room 
temperature. After washing four times, 60 μL DI water was added. After being sealed 
with a plastic film, the plate was put to an oven set to 90 ° C for 1 h. After the plate had 
been cooled down to room temperature, 50 μL freshly prepared substrate solution (1.6 
mM TMB and 4.0 M H2O2 in 0.4 M HOAc/NaOAc buffer, pH 4.0) was added to each 
well. After 30 min incubation at room temperature, 50 μL of 2 M H2SO4 as a stopping 
solution was added. The absorbance of each well at 450 nm was read using a microplate 
reader. The procedure of HRP based ELISA was the same as the Pd-Ir NPs@GVs-
based ELISA except for the substitutions of Pd-Ir NPs@GVs-goat antimouse IgG 
conjugates with 100 μL HRP-goat antimouse IgG conjugates (1 μg/mL, in dilution 









The UV-vis spectra were recorded using an Agilent Cary 60 UV-vis 
spectrophotometer. TEM images were taken using a JEOL JEM-2010 microscope 
operated at 200 kV. High resolution TEM (HRTEM) images, high-angle annular dark-
field scanning TEM (HAADF-STEM) images and energy dispersive X-ray (EDX) 
mapping were acquired using a double Cs-corrected JEOL ARM200F TEM at 
Brookhaven National Laboratory. The concentration of Pd, Ir, and Au ions were 
determined using an inductively coupled plasma-optical emission spectroscopy (ICP-
OES, PerkinElmer Optima 7000DV), which could be converted to the particle 
concentration of Pd seeds, Pd − Ir NPs, and Au NPs once the particle sizes and shapes 
had been resolved by TEM imaging. The X-ray photoelectron spectroscopy (XPS) 
measurements were performed on an SSX-100 system (Surface Science Laboratories, 
Inc.) equipped with a monochromated Al Kα X-ray source, a hemispherical sector 
analyzer (HSA) and a resistive anode detector. X-ray diffraction (XRD) pattern was 
taken using a Scintag XDS2000 powder diffractometer. Dynamic light scattering (DLS) 
analysis was conducted using a Photocor-FC light scattering instrument. 1H NMR 
spectra were recorded with a Bruker AV-400 MHz high-resolution NMR spectrometer 
in CDCl3. The absorbance of samples in microtiter plates was read using a PerkinElmer 
Victor 3 1420 Multilabel Plate Reader. Microtiter plates were shaken using a Corning 





Oakton pH 700 Benchtop Meter. Photographs of samples in tubes and microplates were 
taken using a Canon EOS Rebel T5 digital camera. 
 
2.3 Results and discussion 
2.3.1 Synthesis and Characterization of Pd-Ir NPs 
Pd-Ir NPs were synthesized by coating an ultrathin layer of Ir on preformed sub-
10 nm Pd seeds. The Pd-Ir NPs exhibit a high purity (>95%) and good uniformity 
(Figures 2.3a). A close inspection of the NPs shows that the Pd seeds retained their 
truncated octahedral shape after the deposition of Ir, indicating a conformal coating of 
Ir (Figure 2.3b). The average size of the Pd-Ir NPs was measured to be 6.1 nm, which 
was 0.5 nm greater than that of the initial Pd seeds. Therefore, the average thickness of 
the deposited Ir shells was about 0.25 nm, indicating an approximate monolayer coating 







Figure 2.3 Structural and compositional analyses of Pd-Ir NPs prepared by depositing 
Ir atoms on 5.6 nm Pd truncated octahedral seeds. (a,b) low (a) and high (b) 
magnification TEM image of Pd-Ir NPs. The inset is a 2D schematic model. 
 
2.3.2 Peroxidase-like Activity of Pd-Ir NPs 
We quantitatively evaluated the peroxidase-like activity of as-synthesized Pd-Ir 
NPs by apparent steady-state kinetic assay (Figure 2.4). Oxidation of TMB by H2O2 
was chosen as a model catalytic reaction. The catalytic efficiency, in terms of catalytic 
constant (Kcat, which measures the maximum number of colored products generated 
per enzyme/mimic per second), for the Pd-Ir NPs was measured to be 1.1 × 105 s-1. In 
comparison, the values of Kcat for initial Pd seeds and HRP were 4.8 × 10
3 and 4.0 × 
103 s-1, respectively.130 This data suggests that (i) The Pd-Ir NPs are ∼ 28 times more 
efficient than HRP in generating color products (i.e., oxidized TMB with maximum 
absorbance at 653 nm)131,132; and (ii) the enhanced catalytic efficiency for Pd-Ir NPs 







Figure 2.4 Kinetic assays of using Pd-Ir NPs as peroxidase mimics for the oxidation 
of TMB by H2O2. (a) Plot of initial reaction velocity (ν) as a function of TMB 
concentration. (b) Double-reciprocal plot generated from (a), from which the kinetics 
parameters were derived. Error bars in the plots indicate standard deviations of three 
independent measurements. 
 
2.3.3 Encapsulation of Pd-Ir NPs to GVs 
We then encapsulated the Pd-Ir NPs into GVs that were achieved by assembling 
block copolymers (BCPs)-tethered GNPs in an aqueous suspension of Pd-Ir NPs. GNPs 
with a diameter of 33.0 ± 4.7 nm were first modified with thiol-terminated BCPs of 
poly(ethylene oxide)-b-polystyrene (PEO45-b-PS260-SH) and poly(acrylic acid)-b-
polystyrene (PAA23-b-PS250-SH) at a molar ratio of 20:1. It should be mentioned that 
we chose these GNPs of ∼ 33 nm for the assemble of vesicles mainly because (i) the 
ease in the functionalization of GNPs with polymers via Au-S bond, in order to trigger 
the formation of GVs and to conjugate biological moieties for sensing; (ii) the good 
stability of resultant GVs and their capability in retaining molecules (or nanoparticles) 
without noticeable leakage for a long time; our previous studies showed that GVs 
remain stable for months and minimal leakage of small organic molecules (or drugs) 
was observed from GVs after weeks, presumably owing to the jamming of particles in 
the vesicular membranes; in contrast, small molecules tend to leak out from liposomes 
or polymersomes within a few hours, which makes them less attractive for the present 
application;133 (iii) these GNPs are relatively uniform and monodisperse; (iv) the GNP 





convenient to distinguish Pd-Ir NPs from GNPs under electron microscope that is 
critical for monitoring the heat-induced NP release process. 
 
 
Figure 2.5 Electron microscopy characterizations of as-prepared Pd-Ir NPs@GVs. (a,b) 
magnified TEM and SEM images, respectively, showing the overall spherical shape of 
the products. (c) low-magnification SETM image showing the yield and size 
distribution of the products. (d) SEM image of an individual particle with a cavity on 
the GV surface, showing that the GVs were composed of a monolayer of GNPs. 
 
A film rehydration method, which is widely used for scalable fabrication of 
liposomes in pharmaceutic industry, was used to fabricate the GVs. Specifically, 
pristine GVs were prepared by rehydrating a film of BCP-tethered GNPs in water under 
sonication, according to our previously published procedures.44 To encapsulate Pd-Ir 
NPs into GVs, an aqueous suspension of Pd-Ir NPs at a high concentration (∼4.5×1016 
particles/mL) was used for the rehydration process. As indicated by the TEM and 
scanning electron microscopy (SEM) images shown in Figure 2.5, the Pd-Ir NPs@GVs 
showed an overall spherical shape. The low-magnification SEM image demonstrated 
that the Pd-Ir NPs@GVs could be obtained with a high purity and a good uniformity. 
Our analyses on 100 random particles indicated that the products had an average 





the GVs were composed of a monolayer of densely packed GNPs, which is consistent 
with our previous studies.44 On the basis of the packing density and size of GV, the 
average number of GNPs in an individual GV was roughly estimated to be 339. The 
loading amount of Pd-Ir NPs in individual GVs was estimated to be 1232 by 
quantifying elemental Pd and Au in GVs using ICP-OES. 
 
2.3.4 Heat-Triggered Release of Pd-Ir NPs 
To demonstrate the heat-triggered release of Pd-Ir NPs from GVs, we incubated 
aqueous suspensions of Pd-Ir NPs@GVs (∼0.5 mg/mL in terms of Au element) at 
different temperatures for 1 h. The morphological change of samples caused by heat 
treatment was monitored by TEM and SEM. We found that the assembled GVs 
gradually collapsed as the temperature increased (Figure 2.6). Compared to the initial 
Pd-Ir NPs@GVs (Figure 2.6a,e), small holes started to appear in the membranes of 
GVs when the temperature was set to 70 ° C (Figure 2.6b, f). At 80 ° C, the holes in 
GVs became more evident and fragments began to fall off from the vesicles (Figure 
2.6c, g). Finally, most of the GVs completely collapsed after 90 ° C treatment (Figure 
2.6d, h). We presume that the dissociation of GNPs is attributed to the breakup of Au-
S bonds due to the thermal instability of the bonds at a temperature above 70° C.134,135 
The disassembly of GVs is associated with the release of encapsulated Pd-Ir NPs 







Figure 2.6 Heat-triggered release of Pd-Ir NPs from GVs. Representative (a-d) TEM 
and (e-h) SEM images of the Pd-Ir NPs@GVs treated at different temperatures (marked 
in each image) for 1 h. In (b-d), insets show magnified TEM images of corresponding 
regions marked by red boxes. Some of the released Pd-Ir NPs are indicated by black 
arrows. 
 
The heat-triggered release of Pd-Ir NPs is further confirmed by dynamic light 
scattering (DLS) analysis. Pristine GVs and Pd-Ir NPs were used as control groups. As 
shown in Figure 2.7, after heating at 90 ° C for 1 h, the major size distribution peak of 
Pd-Ir NPs@GVs suspension shifted from 380 nm (solid, blue) to 260 nm (dashed, blue). 
In addition, two shoulder peaks at ∼ 8.5 nm and ∼ 32 nm were observed. The 8.5 nm 
peak matched well with the peak of pristine Pd-Ir NPs (solid, red), indicating the 
successful release of Pd − Ir NPs from GVs. The 32 nm peak could be assigned to the 
dissociated GNPs from GVs since this peak was also observed for pristine GVs after 
they had been heated (dashed, black). Thermal treatment at 90 ° C for 1 h was adopted 





practical application of the platform for assays. The operation time of assays can be 
drastically reduced by speeding up the release of payload from GVs via the irradiation 
of near-infrared light or the use of thermoresponsive polymer tethers. 
 
 
Figure 2.7 DLS analysis of different samples: GVs (black), Pd-Ir NPs@GVs (blue), 
and Pd-Ir NPs (red) before and after heat treatment (90 °C, 1 h) 
 
2.3.5 Demonstration of signal amplification 
We also designed a set of experiments to demonstrate the color signal amplification 
mechanism shown in Figure 2.1. Briefly, aliquots were taken from an aqueous 
suspension of Pd-Ir NPs@GVs before and after it had been heated at 90 °C for 1 h and 
were employed as catalysts for the oxidation of TMB by H2O2. Colored products were 
quantified by measuring the absorbance at 653 nm, t = 2 min. For comparison, aqueous 





NPs (determined by ICP-OES), respectively, as those in Pd-Ir NPs@GVs were also 
tested. As shown in Figure 2.8, before heat treatment, the reaction solution with the 
presence of Pd-Ir NPs@GVs was nearly colorless with A653nm ≈ 0.04. After heat 
treatment, the catalytic activity of Pd-Ir NPs@GVs was dramatically enhanced, 
generating an intense blue color (A653nm = 1.6, see the inset of Figure 2.8). Since almost 
no absorbance at 653 nm was observed for GVs catalyzed reaction solutions, the 
enhanced catalytic activity for heat treated Pd-Ir NPs@GVs could be ascribed to the 
free Pd-Ir NPs released from GVs. It should be mentioned that, before heat treatment, 
the absorbance of Pd-Ir NPs@GVs catalyzed reaction solution was similar to that of 
GVs catalyzed reaction solution. This observation demonstrated that the GVs could 
effectively prevent the leakage of encapsulated Pd-Ir NPs when there is no heating. On 
the basis of the values of A653nm, heat treated Pd-Ir NPs@GVs was as active as pristine 
Pd-Ir NPs, indicating that most of the Pd-Ir NPs had been released from GVs and their 
catalytic efficiency was well retained. Taken together, these results clearly 







Figure 2.8 Absorbance at 653 nm measured from catalytic reaction solutions 
containing different particles (marked under the bars) at t = 2 min before and after heat 
treatment (90 °C, 1 h). Concentrations of GVs were kept the same for suspensions of 
GVs and Pd-Ir NPs@GVs, while the concentrations of Pd-Ir NPs were kept the same 
for suspensions of Pd-Ir NPs@GVs and Pd-Ir NPs. Inset shows photographs of reaction 
solutions corresponding to Pd-Ir NPs@GVs. 
 
2.3.6 Immunoassay of disease biomarker 
Finally, we applied the Pd-Ir NPs@GVs to ELISA of human prostate surface 
antigen (PSA), according to the principle shown in Figure 2.1. PSA was chosen because 
it has been recognized as the key biomarker responsible for prostate cancer recurrence 
in patients who have undergone radical prostatectomy.136 It is vital to detect minute 
concentrations of PSA at the earliest stage possible to improve the survival rates of 





the EDC/NHS-mediated coupling reaction between the –COOH groups of PAA23-b-
PS250-SH on GVs and the −NH2 groups on antibodies (Figure 2.2).
128 PSA standards 
with a series of concentrations in dilution buffer were monitored in a 96-well microtiter 
plate and quantified using a PerkinElmer Victor 3 1420 multilabel plate reader. The 
yellow color of the wells arose from the two-electron oxidation products of TMB (i.e., 
diimine with λmax ≈ 450 nm) that were formed when the catalytic reaction was quenched 
by H2SO4 (Figure 2.9a).
139 As shown in Figure 2.9b, a sigmoid curve regression 
between the logarithms of absorbance and PSA concentration was obtained. The linear 
range of detection was found to be 0.2-200 pg/mL with a linear regression value of r2 
= 0.997. The coefficient of variations (n = 8) across the entire concentration range were 
2.15 − 12.24%, indicating a good reproducibility of the assay. The limit of detection 
(defined as the PSA concentration corresponding to a signal that is 3 times the standard 
deviation above zero calibrator)140,141 was calculated to be 31 fg/mL. To evaluate the 
nonspecific binding between antibodies conjugated Pd-Ir NPs@GVs and the 96-well 
microtiter plate/capture antibodies, we have performed a control experiment by 
excluding antibodies conjugated Pd-Ir NPs@GVs from the blank well (i.e., 0 pg/mL 
PSA) while keeping all other conditions unchanged. The absorbance at 450 nm for the 
control group was measured to be 0.024, whereas the absorbance for the blank was 
0.036 (both values of absorbance represent the averages from 8 independent 
measurements). Therefore, on average, the absorbance at 450 nm of each well caused 
by nonspecific binding of antibodies conjugated Pd—Ir NPs@GVs was approximately 









Figure 2.9 Pd-Ir NPs@GVs based ELISA of PSA. (a) Representative photographs 
taken from the ELISA of PSA standards; (b) Corresponding calibration curve (■) and 
imprecision profile (□) of the detection results shown in (a). Note that absorbance of 
the blank (i.e., 0 pg/mL PSA) was subtracted from those of PSA standards. Inset shows 
the linear range region of the calibration curve. All the data points represent the 
averages from 8 independent measurements. 
 
We benchmarked the Pd-Ir NPs@GVs based ELISA against the conventional HRP 
based ELISA by using the same set of antibodies and procedures except for the 





the linear detection range and overall coefficient of variations for the HRP based 
ELISA were found to be 0.2-100 ng/mL and 4.21-14.31%, respectively. The limit of 
detection was determined to be 48 pg/mL, which was ∼ 1500-fold higher than our 
enzyme-free ELISA. This significantly enhanced detection sensitivity for the enzyme-
free ELISA could be attributed to the signal amplification by Pd-Ir NPs@GVs, because 
other conditions of both ELISAs were kept identical. We also evaluated the correlation 
between the enzyme-free ELISA with conventional HRP based ELISA by quantifying 
the same 12 PSA standards of concentrations in 0.5-50 ng/mL using the two ELISAs. 
For the quantification with enzyme-free ELISA, the standards were diluted with 
dilution buffer to ensure that the concentrations of PSA were located in the linear range. 
The final quantitative data was obtained based on the detected PSA concentrations and 
the dilution factors. As shown in Figure 2.11, a good correlation between the two 
ELISAs was found with a correlation coefficient r = 0.998 (n = 12). Taken together, 
these results demonstrate that our enzyme-free ELISA is three-orders-of-magnitude 
more sensitive than conventional ELISA, while its reliability and quantitativity are as 







Figure 2.10 Calibration curve (■) and imprecision profile (□) of conventional HRP 
based colorimetric ELISA of PSA, in which PSA standards and antibodies were kept 
the same as what had been used for the Pd-Ir NPs@GVs based ELISA (Figure 2.14).  
Note that absorbance of the blank (i.e., 0 pg/mL PSA) was subtracted from those of 







Figure 2.11 Correlation analysis between the Pd-Ir NPs@GVs based ELISA and HRP 
based ELISA in quantification of PSA from 12 standards. Each data point in the plot 
represents the average from three independent measurements. 
 
2.4 Conclusions 
We have demonstrated an enzyme-free signal amplification technique based on 
Pd-Ir NPs@GVs for colorimetric assay with substantially enhanced detection 
sensitivity. The enzyme-free technique we developed can be potentially extended to a 
variety of other enzymes-based diagnostic technologies beyond ELISA such as 
immunohis-tochemistry, Western blot, and point-of-care tests. Importantly, this 
technique is compatible with equipment and procedures of existing sensing 
technologies, making it practically useful for clinical diagnostics. Further optimization 
of the Pd-Ir NPs@GVs system (e.g., size of GV, loading amount of Pd-Ir NPs, particle 
release time, and catalytic efficiency) and detection of clinical samples are the subjects 













Chapter 3: A universal approach to assemble inorganic 
nanoparticles into hollow vesicles 
 
Overview. In this work, a universal approach was developed to trigger the assembly of 
nanoparticles (NPs) by attaching amphiphilic block copolymers (BCPs) onto oleic acid 
or/and oleylamine capped NPs. Thiol-terminated BCPs were attached onto NPs via a 
one-step ultraviolet-induced thiol–ene reaction, where the double bond in OA (or OAm) 
and thiols in BCPs are coupled into thioether linkage through radical addition. We 
demonstrated that IONPs with various sizes (9.9 nm, 19.5 nm and 30.8 nm) and shapes 
(nanospheres and nanocubes) could be assembled into magnetic vesicles after the 
attachment of amphiphilic BCPs. Furthermore, inorganic nanoparticles with different 
compositions (Cu9S5, MnO and upconversion NPs) were used to fabricate hollow 
vesicles with potential biomedical applications by using this method. 
 




Hollow, inorganic nanoscale vesicles (NVs) have emerged as a remarkable class 
of materials with potential applications in catalysis142, biosensing143, drug delivery77 
and energy storage144, owing to their high surface area, large hollow volume and 
diverse hierarchical architectures and morphologies. Nowadays, one of the most 





which involves multiple steps including the preparation of sacrificial templates, the 
deposition of desired materials onto the templates, and finally the removal of the 
templates by harsh chemical procedures.145-148 Despite its wide application in 
fabrication, it has limitations such as tedious and costly procedures and inevitable 
collapse of the hollow structures during template removal. 
Recently, amphiphilicity-driven self-assembly of “colloidal NPs” was proposed 
and explored as a simple and moderate route to achieve well-defined NVs. Inorganic 
nanoparticles tethered with BCPs are developed as a new class of building blocks for 
the fabrication of vesicular assemblies, in analogy to liposomes or 
polymersomes.43,44,66,149 Thanks to the synergetic coupling between adjacent NPs in the 
assemblies, these hollow NVs exhibit enhanced physical/chemical properties while 
inheriting merits of the primary subunits. However, most of these assembly strategies 
are highly materials-specific and elaborately designed. The attachment of BCPs on NP 
surfaces strongly relies on the interactions between inorganic NPs and functional 
groups of BCPs. For instance, the grafting of BCPs on GNPs is based on the formation 
of Au-S bond, while IONPs are functionalized with BCPs via binding affinity between 
IONPs and dopamine-terminated BCPs.44,50,66,149,150 Therefore, it is highly essential to 
explore novel and universal approaches for simple functionalization of NPs with BCPs 
and preparation of hollow vesicles with nanometer dimensions. 
Herein, we report a simple and generalized approach for the attachment of BCPs 
onto inorganic NPs with various sizes, shapes or compositions, followed by the self-
assembly of the BCP-tethered NPs into NVs. Hydrophobic inorganic NPs capped with 





via a one-step ultraviolet-induced thiol–ene chemistry, where the double bond in OA 
(or OAm) and thiols in BCPs are coupled into thioether linkage through radical addition 
(Figure 3.1).151,152 Driven by the colloidal amphiphilicity originated from the 
conformational rearrangement of grafted BCPs, BCP-NPs could self-assemble into 
well-defined NVs by elaborately tuning the relative sizes of NPs and BCPs. We 
demonstrated successful assembly of IONPs into NVs with potentially enhanced 
magnetization due to the coupling between adjacent subunits. Other inorganic 
nanoparticles such as Cu9S5, MnO and upconversion NPs could be also assembled into 
NVs by using this approach. This work provides a universal strategy for assembling 
OA or OAm-capped inorganic NPs into hollow NVs and opens up an avenue to extend 







Figure 3.1 Schematic illustrating the attachment of BCPs onto OA or/and OAm capped 
NPs via an ultraviolet-induced thiol–ene reaction and assembly of the resultant BCP-




Styrene, 4-cyano-4-(phenylcarbono-thioylthio) pentanoic acid (CPPA), ethanol 
(99.5%), dioxane (99.8%), tetrahydrofuran (THF, 99.9%), methanol (99.9%), n-
butylamine, N-(3-(dimethylamino)propyl)-N’-ethyl-carbodiimide hydrochloride (98%, 
EDC), N-hydroxysuccinimide (98%, NHS), oleic acid (99%), oleylamine (98%), 
hexane (95%), 1-octadecene (90%), 1-hexadecene (98.5%), trioctylamine (98%), 
copper (II) chloride dehydrate, sodium diethyldithiocarbamate trihydrate, manganese 
chloride tetrahydrate, sodium hydroxide (98%), ammonium fluoride, yttrium (III) 
chloride hexahydrate, ytterbium (III) chloride hexahydrate and erbium (III) chloride 
hexahydrate were purchased from Sigma-Aldrich. Azobis(isobutyronitrile) (AIBN) 
was recrystallized from ethanol. Deionized water (Millipore Milli-Q grade) with 
resistivity of 18.0 MΩ was used in all the self-assembly experiments. 
 
3.2.2 Synthesis of Thiol-Terminated BCPs 
Thiol-terminated BCPs of HS-PS-b-PEO were synthesized by the reversible 
addition−fragmentation chain transfer (RAFT) polymerization as reported 





(PEO-CTA), and AIBN were dissolved in dioxane with a molar ratio of 150:1:0.2. The 
solution was filled with nitrogen and then put into a preheated oil bath at 85 °C for 20 
h. The product was precipitated in hexane and dissolved in THF to remove unreacted 
monomers and impurities. Molecular weight of the BCPs characterized by 1H NMR 
was 11.0 kg/mol, by comparing the integrals of the resonance peaks of aromatic ring 
of PS block (6.4 − 7.3 ppm) and the methylene groups of PEO-CTA (3.65 ppm) (Figure 
3.2b).The CTA-PS98-b-PEO17 was dissolved in THF with excess of n-butylamine under 
nitrogen for 4 h to convert CPPA into thiol groups. The resulting HS-PS98-b-PEO17 was 
obtained by precipitation in hexane twice and dried under vacuum for 24 h. 
 
3.2.3 Synthesis of Oleic Acid and/or Oleylamine-capped Nanocrystals 
Hydrophobic IONPs with various sizes were prepared via thermal decomposition 
of iron oleate complex by using oleic acid as the stabilizing agent.153 Briefly, iron oleate 
complex (3.6 g, 4 mmol) and oleic acid (0.57 g, 2 mmol) were dissolved in 1-
octadecene (20 g) at room temperature. The mixture was heated to 300 °C with a 
constant heating rate and then kept at this temperature for 30 min. The resulting solution 
containing IONPs (19.45±0.73 nm) was then cooled to room temperature and washed 
with ethanol three times. The precipitated IONPs were dispersed in THF to form a 
stable colloidal solution with a concentration of 5 mg mL−1. By switching 1-octadecene 
into 1-hexadecene and trioctylamine, OA-capped IONPs of 9.85±0.48 nm and 
30.81±2.03 nm were prepared respectively, due to the change of solvent boiling point. 





that a mixture of oleic acid (0.28g, 1mmol) and sodium oleate (0.30g, 1mmol) were 
added before thermal decomposition of iron oleate complex. 
OAm-capped Cu9S5 NPs were prepared by a modified thermal decomposition 
process.154 Copper diethyldithiocarbamate [Cu(DEDTC)2] precursor was prepared by 
reacting CuCl2·2H2O with sodium diethyldithiocarbamate (SDEDTC) as follows: A 
solution of SDEDTC (10 mmol) in distilled water (5 mL) was added into another 
solution containing CuCl2 (10 mmol) and distilled water (10 mL) under magnetic 
stirring for 1h, forming a dark brown turbid solution. Subsequently, the dark brown 
Cu(DEDTC)2 precursor was obtained by filtration and dried at room temperature under 
vacuum before use. For the synthesis of OAm-capped Cu9S5 NPs, 15 mL of OAm was 
slowly heated to 300 °C in a flask under magnetic stirring and N2 for 30 min to remove 
residual water and oxygen, followed by the injection of 5 mL OAm containing 1 mmol 
Cu(DEDTC)2. The resulting solution became dark green immediately and the reaction 
was kept at 300 °C for 10 min and then cooled to 60 °C naturally. The resulting solution 
was washed with ethanol three times and the precipitated Cu9S5 NPs were collected by 
centrifugation and dispersed in THF to form a stable colloidal solution with a 
concentration of 5 mg mL−1. 
OA-capped MnO NPs were prepared via thermal decomposition of manganese 
oleate precursor.155 Manganese oleate complex was prepared according to a reported 
procedure: 7.94 g (40 mmol) of manganese chloride tetrahydrate and 22.60 g (80 mmol) 
oleic acid were dissolved in 200 mL of methanol. A solution of 3.2 g (80 mmol) of 
sodium hydroxide in 200 mL of methanol was added dropwise into the Mn-/oleic acid 





followed by the precipitation of a deep red oily substance. After stirred for another hour, 
the solvent was discarded and the precipitates were washed with water, ethanol, and 
acetone. The oily residue was dissolved in hexane and dried over MgSO4. After 
evaporating the solvent, the product was dried in vacuum at 150 °C for 2 h to produce 
a deep red waxy manganese oleate complex. For the synthesis of OA-capped MnO NPs, 
1.24 g (2 mmol) of the manganese oleate precursor was dissolved in 10 g 1-octadecene 
and degassed at 70 °C in vacuum for 2 h. The solution was intermittently backfilled 
with argon to remove any moisture and oxygen. The reaction mixture was subsequently 
rapidly heated to 200 °C with approximately 5 °C/min, followed by another heating 
process of 1.5 °C/min until boiling. The temperature was held at reflux (315 °C) for 1 
h and the as-prepared nanocrystals were washed with ethanol three times by 
centrifugation. MnO NPs were collected and dispersed in THF to form a stable 
colloidal solution with a concentration of 5 mg mL−1. 
OA-capped NaYF4:Yb,Er nanoparticles were synthesized following a reported 
approach.156 Typically, 0.78 mmol YCl3·6H2O, 0.2 mmol YbCl3·6H2O and 0.02 mmol 
ErCl3·6H2O were added into a mixture of 6 mL OA and 15 mL 1-octadecene in a three-
necked flask. The solution was heated to 160 °C for 20 min under argon atmosphere to 
form a transparent solution and then cooled down to room temperature. Subsequently, 
10 mL methanol solution containing 100 mg NaOH and 148 mg NH4F was added 
dropwise into the solution and the mixture was heated slowly to 70 °C under stirring 
for 30 minutes to remove the methanol solvent completely. After the evaporation of 
methanol, the solution was slowly heated to 300 °C and maintained for 1.5 hours under 





washed with ethanol three times and purified by centrifugation. The as-synthesized 
product of NaYF4: 20%Yb, 2%Er UCNPs were dispersed in THF with a concentration 
of 5 mg mL−1. 
 
3.2.4 Synthesis of BCP-tethered NPs 
Thiol-terminated BCPs were attached onto OA and/or OAm capped NPs via an 
ultraviolet-induced thiol–ene reaction. Using IONPs as a model system, 50mg HS-
PS98-b-PEO17 was added into 2 mL of OA-capped IONPs dispersion in THF (30.8 ± 
2.0 nm 5mg mL-1), followed by the addition of 100 µL THF solution of DMPA (10 
mg/mL). The mixture solution was transferred into a sealed quartz beaker and irradiated 
with UV-light (1000 W, 365 nm wavelength) for 60 min in an ice bath under magnetic 
stirring. After completion of UV irradiation, the BCP-tethered IONPs were washed 
with THF for 6 times, collected by centrifugation (12000 rpm/min, 15min) and re-
dispersed in THF with a concentration of 0.2 mg mL-1. To verify successful attachment 
of BCPs onto various inorganic NPs, the hydrodynamic diameter of NPs in THF before 
and after BCPs attachment was measured using a PHOTOCOR-FC light scattering 
instrument with a 5 mW laser of 633 nm at a scattering angle 90°. 1H NMR spectra of 
the NPs and BCP-NPs were also analyzed and compared to confirm the conjugation of 
BCPs onto corresponding NPs. TGA was performed to estimate grafting density of 
BCPs on various NPs. Briefly, the sample (5 mg) was dried and loaded into a platinum 
pan which was heated to 700 ° C at a constant heating rate of 25 °C min−1 under argon. 






𝑓 ∗ 𝑁𝐴 ∗ 𝜌 ∗ 𝑑
6 ∗ 𝑀𝑛 ∗ (1 − 𝑓)
 
Here f refers to the weight fraction of the organic ligands determined by TGA analysis; 
NA is the Avogadro constant; ρ is the bulk density of the corresponding NPs; d is the 
average diameter of BCP-NPs, and Mn is the number-average molecular weight of the 
PEO-b-PS. It is assumed that the density of the BCP-NPs is identical to the density of 
the bulk material and no free polymer is present. 
 
3.2.5 Self-Assembly of BCP-tethered NPs into NVs 
BCP-tethered inorganic NPs were assembled into NVs by film rehydration method. 
As a prototype system, 500 µL THF solution of BCP-IONPs (0.2 mg mL-1) was dried 
on a glass substrate under N2 stream to form a thin film, followed by rehydration in 
water under sonication for 30 s. The as-prepared NVs were collected by centrifugation 
(3000 rpm/min, 15min) and re-dispersed in ultrapure water for further utilization. 
 
3.2.6 Characterizations of NVs 
The assembled NVs were imaged using a Hitachi SU-70 Schottky field emission 
gun Scanning Electron Microscope (FEG-SEM) and a JEOL FEG Transmission 
Electron Microscope (FEG-TEM). Energy dispersive X-ray (EDS) mapping and 
corresponding spectra of the NVs were acquired using a JEOL JEM-2100 LaB6 
Transmission Electron Microscope. Samples for SEM observations were prepared by 





TEM samples were prepared by dropping 5-10 μL of sample solution on 300 mesh 
copper grids covered with carbon film and dried at room temperature. 
 
3.3 Results and discussion 
3.3.1 Synthesis and Characterization of BCP-tethered IONPs 
OA-capped hydrophobic IONPs with a diameter of 30.8 ± 2.0 nm were synthesized 
by a thermal decomposition method reported previously and used as a prototype NP 
for surface modification and self-assembly (Figure 3.2a).153 Thiol terminated PS98-b-
PEO17 (11.0 kg/mol) was synthesized using reversible addition-fragmentation chain-
transfer (RAFT) polymerization and grafted onto the surface of IONPs via ultraviolet-
induced thiol–ene chemistry to obtain amphiphilic building blocks (Figure 3.2b). The 
BCPs-tethered IONPs (BCP-IONPs) remained well dispersed in THF, as confirmed by 
the slightly increased hydrodynamic diameter from 36.4±12.4 nm to 85.9±22.8 nm 
after treatment, owing to the BCPs layer grafting on the surface of IONPs (Figure 3.3a). 
The average grafting density (σ) of BCPs is estimated to be 0.08 chains/nm2 based on 
















Figure 3.3 (a) DLS diameter of IONPs before and after the attachment of BCPs and (b) 
TGA analysis of BCP-IONPs. 
 
3.3.2 Synthesis and Characterization of NVs assembled from BCP-tethered IONPs 
Assemblies of IONPs were fabricated by rehydrating a film of BCP-IONPs in 
ultrapure water and the formation of vesicular structures can be attributed to the 
conformation change of BCP tethers on NP surface, as we reported previously.44 
Scanning and transmission electron microscope (SEM/TEM) images in Figure 3.4a, b 
show that the resulting NVs were composed of multilayers of densely packed IONPs 
in the vesicular membranes. The hollow interior and multilayers of IONPs in the 
membrane can be clearly seen from NVs with occasionally broken membrane (inset in 
Figure 3.4a). The average diameter of the MuMVs was estimated to be 679.2 ± 53.8 
nm by TEM analysis (Figure 3.4c). The composition of NVs was further confirmed by 
EDS element mapping, where strong Fe and O signals were observed, indicating that 







Figure 3.4 (a) SEM and (b) TEM images of magnetic vesicles assembled from PEO-
PS-OA-SPIONs; (c) Size distribution of magnetic vesicles from TEM analysis; (d) 
EDS mapping of magnetic vesicles showing the element of Fe and O 
 
3.3.3 Influence of BCPs length and NPs size on the vesicle formation 
Similar to the assembly of BCP-GNPs, the self-assembly of BCP-IONPs is 
strongly dependent on the hydrophilic/hydrophobic balance of the building blocks. To 
investigate the factors influencing the assembly morphologies, IONPs of various sizes 
and BCPs with different length of PS (at fixed length of PEO17) were synthesized and 
used to produce building blocks of NVs (Figure 3.5). With the increase of MW of BCP 
tethers from 6.2 k to 14.5 k, the assembly morphologies transited from clusters to 
vesicles and eventually to random aggregates for BCP-IONPs of all sizes due to an 
increase in overall hydrophobicity (Figure 3.6). Meanwhile, at fixed MW of BCP (e.g., 





observed when the size of IONPs increased. This is mainly attributed to the decreased 
graft density of BCPs associated with a decreased curvature for larger IONPs. NVs 
composed of BCP-tethered iron oxide nanocubes were also fabricated using the same 
strategy, indicating this assembly-based approach is applicable to IONPs with various 







Figure 3.5 (a-c) TEM and size analysis of IONPs with various diameter of (a) 





BCPs: (d) PEO17-b-PS52, (e) PEO17-b-PS70, (f) PEO17-b-PS85, (g) PEO17-b-PS98,(h) 
PEO17-b-PS111 and (i) PEO17-b-PS132 
 
 
Figure 3.6 SEM images of vesicular assemblies from BCP-tethered IONPs with 
different diameters: (a-d) 10 nm, (e-h) 19 nm, and (i-l) 31 nm. BCPs with different 
lengths used here are: (a,e,i) PEO17-b-PS70, (b,f,j) PEO17-b-PS85, (c,g,k) PEO17-b-PS98 
and (d,h,l) PEO17-b-PS111. (m) The product diagram for the self-assembly of BCP-
IONPs with varying diameter of IONPs and molecular weight of PEO17-b-PSx. (□) 







Figure 3.7 TEM images of (a) Fe3O4 nanocubes and (b) vesicles assembled from PEO-
PS-OA-capped Fe3O4 nanocubes. 
 
3.3.4 Self-assembly of BCP-tethered NPs with various compositions 
We demonstrated that this assembly-based approach is applicable to colloidal NPs 
with different compositions, surface ligands and morphologies. Three other 
hydrophobic NPs including OAm-capped Cu9S5 (Figure 3.8a 19.7 ± 4.4 nm), OA-
capped MnO (Figure 3.8b 27.2 ± 8.7 nm) and OA-capped upconversion NPs 
(NaYF4:Yb3+, Er3+ Figure 3.8c 44.0 ± 6.5 nm) were prepared and used for assembly.154-





characteristics as BCP-IONPs (Figure 3.9a). The average grafting density (σ) of BCPs 
is estimated to be 0.10 (MnO NPs), 0.09 (CuS NPs) and 0.08 (UCNPs) chains/nm2 
according to the thermogravimetric analysis (Figure 3.9b). NVs composed of the 
corresponding NPs were observed by both SEM and TEM which clearly revealed the 
hollow interior of the assemblies with the occasionally broken membrane (Figure 
3.10a-l). The composition of NVs was verified by EDS element mapping, which 




Figure 3.8 TEM images of (a) OAm-capped Cu9S5 NPs, (b) OA-capped MnO NPs and 







Figure 3.9 (a-c) DLS diameter of (a) Cu9S5 NPs, (b) MnO NPs and (c) UCNPs before 
and after the attachment of BCPs. (d-f) TGA analysis of (d) BCP-Cu9S5 NPs (e) BCP-







Figure 3.10 (a,b) SEM and (c,d) TEM images of vesicles assembled from PEO-PS-
OAm-Cu9S5 NPs; (e,f) SEM and (g,h) TEM images of vesicles assembled from PEO-
PS-OA-MnO NPs; (i,j) SEM and (k,l) TEM images of vesicles assembled from PEO-
PS-OA-UCNPs; (m-o) EDS mapping of (m) Cu9S5 vesicles showing the element of Cu 
and S; (n) MnO vesicles showing the element of Mn and O and (o) UCNP vesicles 
showing the element of Y, Yb and Er. 
 
3.4 Conclusions 
In summary, we have developed a universal strategy to attach BCPs onto inorganic 
NPs to produce colloidal amphiphiles for self-assembly. Thiol-terminated BCPs were 
conjugated with OA or/and OAm on NP surface via an ultraviolet-induced thiol–ene 
reaction, followed by the self-assembly of BCP-NPs into well-defined hollow vesicles. 
By using this approach, NPs of various sizes, shapes and compositions were assembled 
into vesicles respectively, which may find a range of applications in such as bioimaging, 













Chapter 4: Cooperative Assembly of Magneto-nanovesicles 
with Tunable Wall Thickness and Permeability for MRI-
guided Drug Delivery 
 
Overview. Although various approaches have been developed for the fabrication of 
vesicles with inorganic NPs as building blocks, a lack of control over assembly 
structures and properties significantly limits their further applications. Here we 
describes the fabrication of nanosized magneto-vesicles (MVs) comprising tunable 
layers of densely packed superparamagnetic iron oxide nanoparticles (SPIONs) in 
membranes via cooperative assembly of polymer-tethered SPIONs and free 
poly(styrene)-b-poly(acrylic acid) (PS-b-PAA). The membrane thickness of MVs 
could be well controlled from 9.8 to 93.2 nm by varying the weight ratio of PS-b-PAA 
to SPIONs. The increase in membrane thickness was accompanied by the transition 
from monolayer MVs, to double-layered MVs and to multilayered MVs (MuMVs). 
This can be attributed to the variation in the hydrophobic/hydrophilic balance of 
polymer-grafted SPIONs upon the insertion and binding of PS-b-PAA onto the surface 
of nanoparticles. Therapeutic agents can be efficiently encapsulated in the hollow 
cavity of MVs and the release of payload can be tuned by varying the membrane 
thickness of nanovesicles. Due to the high packing density of SPIONs, the MuMVs 
showed the highest magnetization and transverse relaxivity rate (r2) in magnetic 
resonance imaging (MRI) among these MVs and individual SPIONs. Upon intravenous 





effectively enriched at tumor sites due to synergetic effect of magnetic and active 
targeting. As a result, they exhibited drastically enhanced signal in MRI, improved 
tumor delivery efficiency of drugs as well as enhanced antitumor efficacy, compared 
with groups with only magnetic or active targeting strategy. The unique nanoplatform 
may find applications in effective disease control by delivering imaging and therapy to 
organs/tissues that are not readily accessible by conventional delivery vehicles. 
 
This chapter is adapted from the manuscript published in the following article: Yang, 
K., Liu, Y., Liu, Y., Zhang, Q., Kong, C., Yi, C., Zhou, Z., Wang, Z., Zhang, G., Zhang, 
Y., Khashab, N., Chen, X. and Nie, Z., Cooperative Assembly of Magneto-
Nanovesicles with Tunable Wall Thickness and Permeability for MRI-Guided Drug 
Delivery, J. Am. Chem. Soc., 2018, 140, 4666−4677 
 
4.1 Introduction 
Superparamagnetic iron oxide nanoparticles (SPIONs) have been widely explored 
for biomedical applications, such as biosensing,158 immunoassay,159 cell separation,160 
and cancer imaging and therapy,161-165 due to their unique size, biocompatibility, 
biostability, and responsiveness to magnetic field.166-169 For instance, SPIONs can 
serve as negative magnetic resonance imaging (MRI) contrast agents, as they can 
shorten the transverse relaxation time (T2) of water protons, resulting in a hypointense 
signal in T2-weighted MRI.
78 The magnetic movement of SPION-based nanocarriers 
can be used to guide the delivery of therapeutic agents specifically to diseased areas to 
achieve optimal therapy outcomes. However, small SPIONs inherently possess a 
relatively low magnetization per particle, making it difficult to readily manipulate their 





(NPs) (e.g., above ∼ 26 nm) leads to a higher magnetic moment, but at the expense of 
inducing a superparamagnetic/ferromagnetic transition and hence possible colloidal 
instability of NPs.171 One promising strategy of resolving this issue is to assemble 
SPIONs into larger ensembles and utilize the magnetic properties of a collection of NPs 
for medical imaging and targeted delivery.32,36,37,99,172-174 
Nanosized vesicles (e.g., liposomes or polymersomes) are particularly attractive 
and have made the greatest clinical impact, because of their unique ability to 
encapsulate and deliver hydrophilic and/or hydrophobic compounds 
simultaneously.175-178 Incorporating SPIONs into organic vesicular membranes can 
impart the system with magneto-responsiveness in order to develop highly selective 
and effective therapeutics and diagnostics.179-182 One commonly used strategy for the 
fabrication of SPION-embedded nanovesicles is to coassemble hydrophobic small 
molecular ligand-covered SPIONs with amphiphilic lipids or block copolymers 
(BCPs).183-186 During the assembly, SPIONs are inserted into the hydrophobic domains 
(e.g., center of lipid bilayers) of vesicular membranes through hydrophobic interaction 
between capping agents and hydrophobic segments of lipids or BCPs. Small NPs (<8 
nm) are usually used in the fabrication, in order to avoid possible insertion-induced 
morphological change or hole formation of vesicles. More recently, the assembly of 
BCP-tethered NPs has provided an effective route to the fabrication of hybrid vesicles 
with high density and much broader size range of NPs in the membrane.43,44,66 These 
hybrid vesicles have been demonstrated for enhancing MRI and photoacoustic imaging, 
as well as efficacy in photothermal/photodynamic therapy due to their collective 





dependent on the content and organization of SPIONs in individual ensembles, it is 
expected that vesicles with thicker SPIONs-bearing membrane could demonstrate 
higher imaging contrast and magnetization for better in vivo imaging and drug delivery. 
Nevertheless, there remains challenging in the fabrication of hybrid vesicles with 
tunable layers of NPs in the membranes. 
Here we report the design of magneto-vesicles (MVs) composed of tunable layers 
of densely packed SPIONs via cooperative assembly of polystyrene-b-poly(ethylene 
oxide) (PS-b-PEO)-tethered SPIONs and free poly(styrene)-block-poly(acrylic acid) 
(PS-b-PAA) (Figure 4.1a). The membrane thickness of MVs can be controlled from 
9.8 to 93.2 nm by varying the weight ratio of PS-b-PAA to SPIONs, which is 
accompanied by the transition from monolayer MVs (MoMVs), to double-layered MVs 
(DoMVs) and to multilayered MVs (MuMVs). The formation of MVs with controlled 
layers of SPIONs is attributed to the modulation of the surface property of SPION 
building blocks through the binding interaction between carboxyl groups of PS-b-PAA 
and SPIONs. Compared with individual SPIONs, MVs with a thicker membrane 
exhibit a much higher magnetization for magnetic manipulation as a result of larger 
amounts of SPIONs in each vesicle. Moreover, as the membrane thickness of MVs 
increases, a higher magnetization leads to a drastically enhanced transverse relaxivity 
rate (r2) value in MRI due to the higher density of SPIONs. Therapeutic agents such as 
doxorubicin (Dox) can be efficiently encapsulated in the hollow cavity of MVs during 
the assembly process and the release of payload can be tuned by varying the membrane 
thickness of the MVs. Upon intravenous injection into athymic nude mice implanted 





MuMVs (RGD-Dox-MuMVs) exhibited significantly enhanced tumor accumulation 
via synergistic magnetic field-enhanced targeting and RGD-mediated active targeting 
of tumors (Figure 4.1b). As a result, RGD-Dox-MuMVs with a magnetic field showed 
over 10-fold increase in the delivery of Dox in tumors and drastically enhanced tumor 
inhibition, compared with control groups without RGD and magnetic field. We expect 
that the unique nanoplatform may find applications in effective disease control by 
delivering imaging and therapy to organs/tissues that are not readily accessible by 







Figure 4.1 (a) Fabrication of MVs with tunable wall thickness via cooperative 
assembly of BCP-grafted SPIONs and free PS-b-PAA and (b) utilization of MVs for 
imaging-guided magnetic delivery of Dox into tumor-bearing mice. 
 
4.2 Experiments  
4.2.1 Materials 
Dopamine hydrochloride, 6-maleimidohexanoic acid N-hydroxysuccinimide ester, 
triethylamine ( ≥ 99.5%, TEA), styrene, azobis(isobutyronitrile) (AIBN), 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid (CPPA), dioxane, tetrahydrofuran (THF), 
N,N-dimethylformamide (DMF), n-butylamine, N-hydroxysuccinimide (98%, NHS), 
N-(3-(dimethylamino)propyl)-N’-ethyl-carbodiimide hydrochloride (98%, EDC), 
oleic acid (99%), 1-octadecene, doxorubicin hydrochloride (98.0 − 102.0%), 
Dulbecco’s modified Eagle’s medium (DMEM), 2-(4-Amidinophenyl)-6-
indolecarbamidine dihydrochloride (DAPI dihydrochloride), and fluoresceinamine 
isomer I were purchased from Sigma-Aldrich. Polystyrene-b-poly(acrylic acid) (PS106-
b-PAA4) was purchased from Polymer Source Inc. Fetal bovine serum (FBS), DPBS, 
trypsin-EDTA and penicillin/streptomycin (5000 U mL−1) were purchased from 
Thermo Fisher Scientific. 
 
4.2.2 Synthesis of SPIONs and Dopamine-Terminated BCPs 
Hydrophobic SPIONs were prepared via thermal decomposition of iron-oleate 





(3.6 g, 4 mmol) and oleic acid (0.57 g, 2 mmol) were dissolved in 1-octadecene (20 g) 
at room temperature. The mixture was heated to 300 ° C with a constant heating rate 
and then kept at this temperature for 30 min. The resulting solution containing SPIONs 
was then cooled to room temperature and washed with ethanol three times. The 
precipitated SPIONs were dispersed in THF to form a stable colloidal solution with a 
concentration of 5 mg mL−1. 
Thiol-terminated BCPs of HS-PS260-b-PEO45 were synthesized by the reversible 
addition-fragmentation chain transfer (RAFT) polymerization as reported previously.44 
Briefly, styrene, chain transfer agent (PEO-CTA), and AIBN were dissolved in dioxane 
with a molar ratio of 300:1:0.2. The solution was filled with nitrogen and then put into 
a preheated oil bath at 85 ° C for 20 h. The product was precipitated in hexane and 
dissolved in THF to remove unreacted monomers and impurities. Molecular weight of 
the BCPs characterized by 1H NMR was 29.0 kg/mol, by comparing the integrals of 
the resonance peaks of aromatic ring of PS block (6.4-7.3 ppm) and the methylene 
groups of PEO-CTA (3.65 ppm) (Figure 4.2a).The CTA-PS 260 -b-PEO 45 was 
dissolved in THF with excess of n-butylamine under nitrogen for 4 h to convert CPPA 
into thiol groups. The resulting SH-PS260-b-PEO45 was obtained by precipitation in 
hexane twice and dried under vacuum for 24 h. 
Dopamine-terminated BCPs were synthesized by reacting maleimide-terminated 
dopamine with thiol-terminated BCPs through a Michael addition reaction. Briefly, 
maleimide-terminated dopamine was first synthesized by the carbodiimide reaction 
following a previously reported procedure.187 Maleimide-terminated dopamine (346 





mL DMF and the mixture was stirred under nitrogen for 120 h. The dopamine-
terminated BCPs were obtained by precipitating in water/ethanol mixture (1/3, vol) 
three times and dried under vacuum for 24 h. The synthesized polymers were dissolved 
in CDCl3 and characterized by 
1H NMR (Figure 4.2b) 
 
 
Figure 4.2 1H NMR spectrum of (a) PEO-b-PS and (b) dopamine-terminated PEO-b-
PS 
 
4.2.3 Surface modification and self-assembly of SPIONs into magneto-vesicles 
Surface Modification of SPIONs. SPIONs were modified with amphiphilic BCPs 
via the chelation of dopamine with the surface of SPIONs. Briefly, SPIONs (5 mg) and 
dopamine-terminated BCPs (15 mg) were dispersed in THF (5 mL), and the mixture 
was incubated for 48 h. The solvent was evaporated and the SPIONs were washed with 
DMF for 5 times to remove excess BCPs. The purified BCP-tethered SPIONs were 





grafting density of BCPs on SPIONs. Briefly, the sample (5 mg) was dried and loaded 
into a platinum pan which was heated to 720 °C at a constant heating rate of 25 °C 
min−1 under argon. The BCPs grafting density (σ) was calculated using the formula: 
σ =
𝑓 ∗ 𝑁𝐴 ∗ 𝜌 ∗ 𝑑
6 ∗ 𝑀𝑛 ∗ (1 − 𝑓)
 
Here f refers to the weight fraction of the organic ligands determined by TGA analysis; 
NA is the Avogadro constant; ρ is the bulk density of SPIONs (5.15 g cm−3); d is the 
average diameter of SPIONs, and Mn is the number-average molecular weight of the 
PEO-b-PS. It is assumed that the density of the SPIONs is identical to the density of 
the bulk material and no free polymer is present. 
Self-Assembly of SPIONs. BCP-tethered SPIONs were assembled into MVs by 
film rehydration method. Briefly, BCP-tethered SPIONs (100 μg) were mixed with 
predetermined amount of PS106-b-PAA4 in THF. The mixture was dried to form a thin 
film in a glass vial under N2 stream, followed by rehydration in water or an aqueous 
solution of Dox under sonication for 30 s. The MVs with controlled wall thickness were 
collected by centrifugation at 2000 rpm for 15 min. By adjusting the amount of PS106-
b-PAA4 (80 μg 160 μg, 240 μg and 320 μg), MuMVs with various membrane thickness 
were achieved. MoMVs were prepared in a similar way except that no PS106-b-PAA4 
was added. For the modification of MuMVs, RGD peptides (or fluoresceinamine, FL), 
DCC, NHS, and PS 106 -b-PAA 4 were dissolved in DMF with a molar ratio of 
1:1.5:1.5:1, followed by mechanical stirring for 24 h and precipitation in water/ethanol 
mixture (1/3, vol) to obtain functionalized BCPs for further self-assembly. Surface-
functionalized MuMVs could be obtained by using the RGD and/or FL-conjugated PS-






The assembled MVs were imaged using a Hitachi SU-70 Schottky field emission 
gun Scanning Electron Microscope (FEG-SEM) and a JEOL FEG Transmission 
Electron Microscope (FEG-TEM). Samples for SEM observations were prepared by 
dropping 5-10 μL of sample solution onto silicon wafers and dried at room temperature. 
TEM samples were prepared by dropping 5-10 μL of sample solution on 300 mesh 
copper grids covered with carbon film and dried at room temperature. To verify the 
vesicular structures of MuMVs, TEM images at different tilt angles (−60° to 60°) were 
recorded using electron microscopic tomography. The hydrodynamic diameter of MVs 
in solution was measured using a PHOTOCOR-FC light scattering instrument with a 5 
mW laser of 633 nm at a scattering angle 90°. The zeta potential of MVs in solution 
was measured using a SZ-100 nanoparticle analyzer. To study the mechanism of MVs 
formation, PEO-b-PS-SPIONs were washed with THF for 3 times after addition of PS-
b-PAA and used for TGA analysis and DLS evaluation. 
 
4.2.5 Magnetic properties and magnetic relaxivity of MVs 
Magnetic properties of MVs. Magnetic property measurements were performed 
using a Quantum Design MPMS 3 Superconducting Quantum Interference Device 
(SQUID). The magnetic moment M of both MVs and individual SPIONs was measured 
as function of applied magnetic field H at room temperature and low temperature. The 
magnetic moment of an individual grain (µ) can be determined by the Langevin 
paramagnetic function: M(x)=Nµ(cothx-(1/x)), where x=µH/kBT, N is the number of 





temperature. In this experiment, T is 300K. We let B=µ/kBT and C=Nµ (B and C are 
constants to be determined). Fitting the data of M(x) and H into the Langevin function, 
two constants B and C were determined. Finally the magnetic moment per grain can be 





-17 emu). The magnetic movement of an individual 
SPION is the magnetic moment of an individual grain as they are dispersed individually 
in an aqueous solution (MSPIONs=µSPIONs=8.28E
-17 emu). However, the magnetic 
moment of a MV is the sum of the magnetic moment of all the subunits within the 






where Vmb is the volume of membrane calculated by Vmb=
4𝜋(𝑅3−𝑟3)
3
 (R is the radius 
of vesicle and r is the radius of cavity), 𝜎𝑚𝑏
𝑆𝑃𝐼𝑂𝑁𝑠 is the volume fraction of SPIONs inside 
the polymer membrane calculated by their weight ratio of SPIONs relatively to the 
copolymers, and VSPIONs is the volume of an individual SPION calculated by 𝑉𝑆𝑃𝐼𝑂𝑁𝑠 =
𝜋𝐷3
6
 (D is the average diameter of SPIONs). Here NSPIONs was calculated to be 945, 2020 






Magnetic relaxivity measurements of MVs. The T2 relaxivity times of individual 
SPIONs, MoMVs, DoMVs and MuMVs were measured at a series of different sample 
concentrations using a micro-MR scanner (7.0 T, Bruker, Pharmascan) with small 





series inductively coupled plasma-optical emission spectrometer (ICP-OES). Briefly, 
a concentrated stock solution of different samples (200 µL) was added to scintillation 
vials. Then, 1 mL of aqua regia was added to each vial to dissolve all iron oxide 
nanoparticles. Finally, 9 mL of deionized water was added to the vials. The Fe 
concentrations of the prepared solutions were then measured using ICP-OES. The T2 
relaxivity times were plotted as a function of iron concentration to obtain the r2 value 
of each sample. 
 
4.2.6 Encapsulation and release of Dox from MVs 
Dox-loaded MVs were prepared by rehydrating a film of BCP-tethered SPIONs in 
aqueous solutions of Dox, followed by centrifugation for six times to remove free drug 
molecules. The loading content of Dox in MuMVs (LDox) can be calculated by 𝐿𝐷𝑜𝑥 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐷𝑜𝑥 𝑖𝑛 𝑀𝑢𝑀𝑉𝑠
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑀𝑢𝑀𝑉𝑠
∗ 100%, where mass of MuMVs was measured using ICP-OES 
and mass of Dox in MuMVs was evaluated using a fluorescence spectrometer. Dox 
solutions with predetermined concentration of Dox (from 0.1 to 2.0 mg mL−1) were 
used for the fabrication of Dox-loaded MuMVs (at constant MuMVs concentration of 
0.2 mg mL−1). For the drug release experiment, 1 mL solution of the Dox-loaded MVs 
was transferred to a dialysis tube with a molecular weight cutoff of 6000-8000 g/mol, 
which was incubated in a 50 mL PBS reservoir at 37 °C. One mL solution from the 
reservoir was taken at scheduled time intervals and its fluorescence emission at 590 nm 





the vesicles. After each measurement, the 1 mL solution was put back into the reservoir 
to maintain the total volume of the buffer solution. 
 
4.2.7 In vitro cellular uptake and cytotoxicity of MuMVs 
Cellular uptake of MuMVs. The human malignant glioma cell line (U87MG) were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C in a humidified 5% CO2 
atmosphere. Cells were seeded into chambered glass cover slides and grown for 24 h. 
Then the culture medium was replaced with fresh medium containing saline, Dox-
loaded fluoresceinamine-functionalized MuMVs (FL-MuMVs), and Dox-loaded 
fluoresceinamine and RGD functionalized MuMVs (FL-RGD-MuMVs), respectively 
(Fe concentration: 0.02 mg mL−1). After incubation for 1 h, the cells were washed three 
times with PBS and fixed in a 4% paraformaldehyde/PBS solution for 10 min. The 
fixative was then removed, and cells were washed again with PBS for three times and 
incubated with DAPI for cellular nuclei staining. The slides were washed with PBS and 
then observed by a confocal microscope (Zeiss LSM 710) with appropriate band-pass 
filters for collection of DAPI, FL, and Dox emission signals. 
For TEM observations of the vesicles after cellular internalization, the FL-RGD-
MuMVs were loaded into U87MG cells as described previously, except that a 
monolayer of cells were grown on Thermanox@Plastic Coverslips placed inside 6-well 
cell-culture plates. After incubation with FL-RGD-MuMVs for 1 h, the culture medium 
was replaced by the fixation solution containing 2.5% paraformaldehyde and 2.0% 





and samples were then washed in 0.1 M sodium cacodylate buffer for three times. The 
samples were dehydrated and subsequently infiltrated with Epon-Aradite for 24 h, 
followed by polymerization at 60 ° C for 24 h. Ultrathin sections were cut on a Leica 
EM UC6 Ultramicrotome (Leica, Buffalo Grove, IL) and collected on copper slot grids 
for TEM observations. 
Cytotoxicity of Dox, MuMVs, Dox-MuMVs, and RGD-Dox-MuMVs. Cytotoxicity 
of Dox, MuMVs, Dox-loaded MuMVs (Dox-MuMVs), and RGD-Dox-MuMVs on the 
U87MG cells were evaluated using the MTT assay.188 Briefly, cells were plated at a 
density of 1 × 104 in 96-well plates and cultured at 37 °C for 24 h. Then the culture 
medium was replaced and the cells were incubated with different concentrations of Dox, 
MuMVs, Dox-MuMVs, and RGD-Dox-MuMVs for 1 h. The concentrations of Fe in 
MuMVs, Dox-MuMVs, and RGD-Dox-MuMVs as well as the concentrations of Dox 
in free drug, Dox-MuMVs, and RGD-Dox-MuMVs groups were kept constant for the 
purpose of comparison. Then the culture medium was replaced with fresh medium, and 
the cells were incubated for another 12 h, followed by the addition of 20 μL of the MTT 
solution (5 mg mL−1). After incubation for 4 h, culture supernatants were carefully 
removed and 100 μL of DMSO was added into each well to dissolve the purple 
precipitate. The concentration of the reduced MTT in each well was determined 
spectrophotometrically by subtraction of the absorbance reading at 650 nm from that 
measured at 570 nm using a microplate reader (SpectraMax M5). Cell viabilities were 
presented as the percentage of the absorbance of Dox, MuMVs, Dox-MuMVs, and 
RGD-Dox-MuMVs treated cells to the absorbance of nontreated cells and plotted as Fe 






4.2.8 In vivo MRI though intravenous administration 
All animal experiments were performed under a National Institutes of Health 
Animal Care and Use Committee (NIHACUC) approved protocol. Tumor-bearing 
mice were achieved by subcutaneously injecting ∼ 2 × 106 U87MG cells into the right 
hind leg of athymic nude mice. After the tumor volume exceeded 100 mm3, MR 
imaging of tumor tissues was recorded as background on a high magnetic field micro-
MR scanner (7.0 T, Bruker, Pharmascan) with small animal-specific body coil. 
Thereafter, the mice were divided randomly into four groups (5 mice in each group) 
and the therapeutic agents (Dox-MuMVs or RGD-Dox-MuMVs) were intravenously 
injected into the tumor-bearing mice at a Dox-equivalent dose of 5 mg/kg and a Fe3O4-
equivalent dose of 65 mg/kg. An external magnetic field was applied on the experiment 
groups for 1 h after injection while for the control groups no magnetic attraction was 
applied. Then MR images were taken to reveal the influence of magnetic attraction, 
RGD functionalization and synergistic magnetic and active targeting strategy on the 
imaging effect of the MuMVs. 
 
4.2.9 In vivo magnetic-guided delivery of Dox though intravenous administration 
The influence of magnetic attraction and RGD-mediated active tumor targeting on 
the delivery efficiency of therapeutic agents was investigated by fluorescence imaging. 
Briefly, Dox-MuMVs or RGD-Dox-MuMVs (5 mg Dox/kg corresponding to a 65 mg 





application of magnetic fields (5 mice in each group). Whole-animal imaging was 
recorded 1 h later by using Maestro in vivo imaging system to monitor the fluorescence 
from Dox. Thereafter the mice were sacrificed and the tumors as well as major organs 
were harvested, washed, and imaged to investigate the in vivo biodistribution of Dox. 
The fluorescence intensities from Dox per unit mass in tumor tissues were also 
evaluated to reflect the effects of magnetic attraction and active tumor targeting on the 
delivery of Dox. 
 
4.2.10 In vivo tumor suppression and mice survival of synergistic magnetic and active 
tumor-targeted delivery of Dox 
The U87MG tumor-bearing mice were randomly divided into six groups with 5 
mice in each group. The first group of mice received PBS, as control group; the second 
group was injected with Dox solution, as “Dox” group; the third group was injected 
with Dox-MuMVs without magnetic attraction, as “magnet- RGD-” group; the fourth 
group was injected with RGD-Dox-MuMVs without magnetic enrichment, as “magnet- 
RGD+” group; the fifth group was injected with Dox-MuMVs under magnetic 
attraction, as “magnet+ RGD−” group; the sixth group was injected with RGD-Dox-
MuMVs under magnetic attraction, as “magnet+ RGD+” group. All the experimental 
groups (2-6 groups) are dispersed in 150 μL PBS before intravenous administration 
with a Dox-equivalent dose of 5 mg/kg. For the groups under magnetic attraction, the 
magnet was applied for 1 h along with injection of therapeutic agents. During half a 
month after the corresponding treatments, the volume of tumors was measured every 





the mice was also evaluated during this period to reveal the systemic toxicity of the 
delivery platform. 
All experiments with live animals were conducted in accordance with a protocol 
approved by the National Institutes of Health Animal Care and Use Committee 
(NIHACUC). In general, the mice must be euthanized when the tumor size reaches 2 
cm, so the mice survival was evaluated based on the life span from the date when the 
mice received treatment to the date when the tumor size reached 2 cm. For each group 
subjected to the corresponding treatment, the survival rate was calculated by dividing 
the number of surviving mice at different days of post-treatment by the total number of 
mice before treatment. 
 
4.3 Results and discussion 
4.3.1 Self-assembly of MVs 
Hydrophobic SPIONs with a diameter of 9.2 ± 0.6 nm were synthesized by a 
thermal decomposition method reported previously (Figures 4.3). Dopamine 
terminated PS260-b-PEO45 (29.0 kg/mol) was synthesized and grafted onto the surface 
of SPIONs to obtain amphiphilic building blocks (Figure 4.4a). The average grafting 
density (σ) of BCPs is estimated to be 0.07 chains/nm2 based on thermogravimetric 







Figure 4.3 TEM images of SPIONs before the self-assembly 
 
 
Figure 4.4 (a) Dynamic light scattering analysis of the hydrodynamic diameter of 
SPIONs in THF before (red) and after (blue) the grafting of amphiphilic PEO-b-PS on 
the surface and (b) TGA results of PEO-b-PS-tethered SPIONs 
 
The MVs were fabricated by rehydrating a film containing both BCP-tethered 
SPIONs and varying amounts of PS106-b-PAA4 in ultrapure water. The formation of 
vesicular structures can be attributed to the conformation change of BCP tethers on NP 
surface, as we reported previously.44,66 Scanning and transmission electron microscope 





multilayers of highly densely packed SPIONs in the vesicular membranes.189 The 
hollow interior and multilayers of SPIONs in the membrane can be clearly seen from 
vesicles with the occasionally broken membrane (inset in Figure 4.5a). These were 
confirmed by TEM observations of MuMVs at different tilt angles (Figure 4.5c). 
Moreover, the two peaks of Fe intensity corresponding to the edge of MVs were 
observed in the energy dispersive X-ray spectroscopy (EDS) line scan of MVs, which 
further supports the formation of vesicles (Figure 4.5d, e). The different width of peaks 
in the two systems also indicates the significant difference in the wall thickness of 
vesicular membranes. The average diameter of the MuMVs was estimated to be 263.3 
± 36.9 nm by TEM analysis. The surface of MuMVs is highly negatively charged (with 
a zeta potential of -75.2 mV), indicating the successful integration of PS-b-PAA chains 
in the vesicular membranes. We found that the MuMVs are stable for days under the 
physiological environment, such as in phosphate-buffered saline (PBS) and PBS 






Figure 4.5 (a) Representative SEM and (b, c) TEM images of MuMVs self-assembled 
from BCP-SPIONs. (d, e) STEM image and Fe intensity line scan for (d) MuMVs and 







Figure 4.6 Hydrodynamic size distribution of MuMVs in PBS and PBS supplemented 
with 10% FBS 
 
4.3.2 Tunable morphology and membrane thickness of MVs 
The formation of MVs with tunable morphology and membrane thickness was 
determined by the relative weight content of PS-b-PAA to SPIONs (WBCP/WSPION) in 
the assembly process. TEM images in Figure 4.7 show the MVs with different 
membrane thickness obtained by varying WBCP/WSPION (at fixed WSPION of 100 μg) for 
assembly. Without the addition of PS-b-PAA, pristine PS-b-PEO-tethered SPIONs 
assembled into MoMVs with a monolayer of SPIONs (Figure 4.7a). This is supported 
by the analysis of membrane thickness: the average wall thickness (TMV) of the 
MoMVs was measured to be 9.8 ± 1.5 nm, which is close to the size of SPIONs (9.2 ± 
0.6 nm) (Figure 4.7e). When WBCP/WSPION ≈0.8, DoMVs were obtained with two layers 





of 24.1 ± 3.8 nm was slightly larger than two times of T MV (19.6 nm) of the monolayer 
membrane, because of the presence of additional PS-b-PAA (Figure 4.7e). Further 
increasing WBCP/WSPION to the range of ∼ 1.6 − 3.2 resulted in the formation of MuMVs 
with more layers of SPIONs (Figure 4.7c, d). Meanwhile, TMV of the MVs increased 
up to 93.2 ± 12.9 nm for MuMVs with the thickest membrane (Figure 4.7e). However, 
at WBCP/WSPION > 3.2, aggregates rather than vesicles were obtained. The coassembly 
of different structures was summarized in a product diagram in Figure 4.7f. With 
increasing amount of PS-b-PAA, the morphology of assemblies underwent a transition 
from MoMVs, DoMVs, to MuMVs, and eventually to random aggregates. At a fixed 
WBCP, a morphological transition from aggregates to MuMVs or from MuMVs to 







Figure 4.7 (a-d) TEM images of MVs with various membrane thicknesses: (a) MoMVs, 
(b) DoMVs, and (c,d) MuMVs. (e) Membrane thickness of MVs as a function of weight 
ratio of PS-b-PAA to BCP-SPIONs (WBCP/WSPION). (f) The product diagram for the 







We presume that the assembly of MVs with controlled membrane thickness is 
attributed to the modulation of the physical property of colloidal building blocks via 
the cooperative interactions between PS-b-PEO grafted SPIONs and free PS-b-PAA. 
Figure 4.8a-c illustrates the hypothetic mechanism of morphological control in the 
assembly. In the absence of free PS-b-PAA, the long, flexible PS-b-PEO chains grafted 
on the NPs undergo conformation change in response to polar solvent water. 
Hydrophilic PEO blocks are preferentially exposed to water while hydrophobic PS 
blocks tend to be shielded from water to minimize the interfacial free energy, thus 
leading to the formation of MVs composed of a monolayer of SPIONs (Figure 4.8a).190-
192 The detailed assembly mechanism has been discussed in our previous work on the 
fabrication of plasmonic vesicles comprising a monolayer of BCP-tethered gold NPs. 
When PS-b-PAA is added in the dispersion of PS-b-PEO grafted SPIONs in THF, the 
free BCPs could bind to the NPs with hydrophobic PS ends extending to the solvent 
media, due to the strong affinity of carboxyl groups to SPIONs. The relatively low σ 
of PS-b-PEO on SPIONs (vs σ = ∼ 0.10 chains/nm2 for thiol-terminated BCPs on GNPs 
of similar size) may also contribute to the insertion of PS-b-PAA in-between PS-b-PEO 
brushes on the surface of SPIONs. Upon the rehydration of dried thin films of such 
mixture in water, the hydrophobic PS ends of inserted PS-b-PAA chains tend to 
segregate away from the nonsolvent, while maximizing the exposure of hydrophilic 
PEO segments of PS-b-PEO brushes. At optimal ratio of WBCP/WSPION, DoMVs with 
bilayer of SPIONs are formed after assembly. Further increasing the amount of PS-b-
PAA leads to an even higher σ of PS blocks on NP surface and the further increase in 





both PS-b-PAA and PS-b-PEO segregated in the center of the vesicular membrane, 
leading to the formation of MuMVs with more layers of SPIONs. 
 
 
Figure 4.8 (a) Mechanism for the formation of MoMVs, DoMVs and MuMVs at 
different WBCP/WSPION due to the cooperative interaction between BCP-grafted 
SPIONs and free PS-b-PAA. (b) Hydrodynamic diameter of SPIONs and (c) weight 
fraction of total BCPs in hybrid BCP-SPIONs with increasing WBCP/WSPION 
 
The mechanism we proposed is supported by our control experiment with free PS-
b-PEO and our evidence on the attachment of PS-b-PAA on the PS-b-PEO grafted 





BCP-SPIONs led to the formation of irregular aggregates rather than MVs with 
controlled layers of SPIONs in membranes (Figure 4.9). Second, the hydrodynamic 
diameter of BCP-SPIONs was found to increase significantly from 30.87 ± 4.44 nm to 
50.97 ± 7.75 nm with increasing feeding ratio of PS-b-PAA, as shown in Figure 4.8b 
(BCP-SPIONs were dispersed in THF for DLS analysis and untethered BCPs were 
removed by careful centrifugation). This could be attributed to a denser polymer layer 
around SPIONs formed by anchoring PS-b-PAA onto NP surface. The same trend was 
also observed in the thermogravimetric analysis (TGA) of the amount of ligands on 
SPIONs with the addition of PS-b-PAA (unattached PS-b-PAA was removed by 
centrifugation). The weight fraction of polymers increased from 15.1% for pristine 
PS-b-PEO-tethered SPIONs to 44.0% for BCP-SPIONs when excess PS-b-PAA was 
added (WBCP/WSPION = 5) (Figure 4.8c). 
 
 
Figure 4.9 Representative SEM images of irregular aggregates assembled from a 





replaced by PS-b-PEO without affinity to the surface of SPIONs, the assembly did not 
produce MVs with tunable layers of SPIONs in the membranes 
 
4.3.3 Magnetic properties of MVs 
The MVs exhibited superparamagnetic properties at room temperature, although 
their overall diameter was well above the threshold size for the 
superparamagnetic/ferromagnetic transition of iron oxide NPs. As shown in the SQUID 
measurement (Figures 4.10a-d), the hysteresis loop of MVs showed no remanence at 
300K, indicating their superparamagnetic behavior similar to that of individual SPIONs. 
By fitting the data from SQUID tests with the Langevin paramagnetic function, the 
magnetic moments for individual SPIONs, MoMVs, DoMVs and MuMVs were 
estimated to be 8.28 × 10−17 emu/particle, 7.79 × 10−14 emu/vesicle, 1.66 × 10−13 
emu/vesicle, and 6.98 × 10−13 emu/vesicle, respectively (Figures 4.10e-i).193 This 
suggests that individual MuMVs can respond more strongly to magnetic field than 
individual SPIONs and other assemblies. When a magnet (3.8 × 3.8 × 2.5 cm3, 0.43 T) 
was applied, MuMVs were completely moved from solution toward the magnet within 
2 min, while SPIONs remained homogeneous in the solution without any visible 
movement for hours (Figure 4.11). The strong magnetic movement of MuMVs makes 







Figure 4.10 Hysteresis curves of (a) SPIONs (b) MoMVs (c) DoMVs and (d) MuMVs 
measured at 300 and 2 K. The magnetization of (e) individual SPIONs, (f) SPIONs in 
MoMVs, (g) SPIONs in DoMVs and (h) SPIONs in MuMVs was obtained by fitting 
the data into the Langevin paramagnetic function. Magnetization of each grain in 
individual SPIONs and MVs and the corresponding net magnetization of SPIONs and 
MVs are summarized in (i) 
 
 
Figure 4.11 Photographs of equal concentrations of aqueous SPIONs and MuMVs 







To evaluate the potential use of MVs in MRI, we quantitatively compared the r2 
values of individual SPIONs, MoMVs, DoMVs, and MuMVs by plotting the inverse 
relaxation times (1/T2) as a function of iron concentration [Fe] (Figure 4.12a). The r2 
value determined by the slope of the plot was 293.6 mM−1 s−1 for MuMVs, which was 
1.8, 2.0, and 2.7 times higher than that for DoMVs (167.1 mM−1 s−1), MoMVs (149.9 
mM−1 s−1), and individual SPIONs (108.7 mM−1 s−1). We presume that the high density 
of SPIONs in the vesicular membranes increased r2 of MuMVs due to enhanced overall 
magnetic moment and magnetization.194-196 The measurements were consistent with the 
trend of the darkness in our T2-weighted MR images with different iron concentrations 
in aqueous dispersion: MuMVs > DoMVs > MoMVs > individual SPIONs (Figure 
4.12b). Thus, we chose MuMVs, which exhibit the highest magnetization and r2 value, 
for our subsequent in vitro and in vivo studies. 
 
 
Figure 4.12 (a) Spin-spin 1/T2 relaxation rates of different nanostructures as a function 
of iron concentration. (b) T2-weighted MRI images of different morphologies with 






4.3.4 In vitro cellular uptake and cytotoxicity of MuMVs 
We evaluated the performance of MuMVs for in vitro targeting and drug delivery 
to tumor cells using Dox as a model drug. The use of film rehydration method enables 
more efficient encapsulation of therapeutic agents than postencapsulation using 
dialysis approach. The loading capacity of Dox in MuMVs could be tuned from 7.8% 
to 27.8% by controlling the concentration of Dox in solutions for rehydration. The 
maximum loading content of 27.8% was achieved with an initial concentration of Dox 
at 1 mg mL−1, while further increase in the initial concentration of Dox in solutions to 
∼ 1.5 mg mL−1 led to a drastic drop in the loading content of Dox in MuMVs. We 
presume that this was attributed to the formation of broken vesicles due to the 
significantly increased viscosity of Dox solution. The release of Dox from the MVs 
was found to be strongly dependent on the composition of the vesicular membrane 
(Figure 4.13a). The release rate of Dox from MVs increased with the increasing 
WBCP/WSPION, while a negligible amount of Dox release (<7%) was observed from 
MoMVs after 48 h. We presume that this can be explained by the impermeability of 
SPIONs to Dox and high mobility of low molecular weight PS106-b-PAA4. When more 
PS-b-PAA are added, the less dense packing of impermeable SPIONs increases the 
transport of Dox molecules through the membranes. Moreover, untethered PS-b-PAA 
chains with high mobility may present in the vesicular membranes, leading to the 







Figure 4.13 (a) In vitro release of Dox from MVs with different contents of PS-b-PAA 
added in the assembly: MV0 (MoMVs, WBCP/WSPION = 0), MV1 (DoMVs, WBCP/WSPION 
= 0.8), MV2 (MuMVs, WBCP/WSPION = 1.6), MV3 (MuMVs, WBCP/WSPION = 3.2). (b) 
Confocal microscope images showing enhanced targeting and Dox delivery from Dox-
loaded FL-RGD-MuMVs to U87MG cells. The nuclei were stained by DAPI and the 
vesicular membranes were labeled with fluoresceinamine. Cells treated with PBS and 
Dox-loaded FL-MuMVs were used as control groups. (Scale bar: 20 μm) (c) In vitro 
cytotoxicity of Dox, Dox-MuMVs, RGD-Dox-MuMVs, and blank MuMVs to U87MG 






Fluoresceinamine (FL) for labeling and RGD peptides for targeting were 
conjugated onto the carboxyl groups of PS-b-PAA via a carbodiimide reaction.197 The 
resultant PS-b-PAA was used to coassemble with BCP-tethered SPIONs to form 
surface-functionalized MuMVs. Subsequently, the FL and RGD conjugated Dox-
MuMVs (FL-RGD-MuMVs) were incubated with U87MG human malignant glioma 
cells for 1 h, followed by confocal laser scanning microscopy (CLSM) imaging. Cells 
treated with saline or FL-labeled Dox-MuMVs without RGD modification (FL-
MuMVs) were used as control groups. Figure 4.13b shows that considerable amount 
of FL-RGD-MuMVs were internalized and distributed in the cytoplasm of U87MG 
cells with the overexpression of αvβ3 integrin that specifically binds to RGD sequence. 
In contrast, the internalization of FL-MuMVs was much lower, as evidenced by a 
weaker green and red fluorescence inside the tumor cells. Minimal green fluorescence 
was observed inside the nucleus as the MuMVs are too large to penetrate nuclear pores. 
However, large amount of Dox could be released from the vesicles and further diffuse 
into the nucleus to inhibit tumor growth after cellular internalization, as evidenced by 
fairly strong red fluorescence throughout the cells. 
The in vitro cytotoxicity of free Dox, MuMVs, Dox-MuMVs, and RGD-Dox-
MuMVs against U87MG cells was evaluated by using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figure 4.13c). No significant 
toxicity was found for cells treated with MuMVs at all studied concentrations. In 
contrast, free Dox, Dox-MuMVs, and RGD-Dox-MuMVs all exhibited a dose-
dependent cytotoxicity on the tumor cells with IC 50 values of 470, 2381, and 474 ng 





efficacy of RGD-Dox-MuMVs to free Dox molecules, both of which could be 
efficiently internalized into tumor cells. Conversely, a much lower tumor inhibition by 
Dox-MuMVs could be attributed to the limited diffusion of Dox from noninternalized 
vesicles into tumor cells, since they were not able to effectively enter tumor cells within 
the incubation period. 
 
4.3.5 In vivo Dox delivery and tumor inhibition of MuMVs 
We assessed the synergistic magnetic field-driven targeting and RGD-based active 
targeting of tumors in athymic nude mice bearing U87MG tumors. The mice were 
intravenously injected with one of the groups: Dox-MuMVs (magnet ±) or RGD-Dox-
MuMVs (magnet ±) at equivalent Dox dose (5 mg Dox/kg corresponding to a 65 mg 
Fe3O4/kg). Subsequently, a magnetic field (0.43 T) was applied for 1 h for the positive 
(+) groups. Compared with mice injected with Dox-MuMVs (magnet −), the 
enhancement in the negative MRI contrast (darkening) in tumors was found to be 
20.1%, 54.6%, and 87.6% from the baseline for the groups of RGD-Dox-MuMVs 
(magnet −), Dox-MuMVs (magnet +), and RGD-Dox-MuMVs (magnet +), 
respectively (Figure 4.14a). The result confirms that intravenously injected MuMVs 
can be effectively enriched in tumors due to the synergistic effect of magnetic and 
active tumor targeting. The magnetic-field enhanced accumulation of MuMVs is more 
significant than individual SPIONs and even micelles or clusters composed of 
SPIONs.198 We expect that a further enhancement in tumor accumulation of MuMVs 







Figure 4.14 (a) In vivo T2-weighted MRI of tumor areas (insets) in U87MG tumor-
bearing mice 1 h after the intravenous injection of different sample groups: Dox-
MuMVs (magnet ±) and RGD-Dox-MuMVs (magnet ±). Red arrows indicate the 
darkened areas in the tumor. (b) In vivo fluorescence imaging of Dox in tumors (insets) 
1 h after the intravenous injection of different sample groups: Dox-MuMVs (magnet ±) 
and RGD-Dox-MuMVs (magnet ±). (c) Quantitative analysis of fluorescence intensity 
in corresponding tumor regions in (b). (d) Tumor growth curve, (e) survival curve and 
(f) body weight variation of U87MG tumor-bearing mice after different treatments: 





Error bars from (c) to (f) represent the standard deviations of 5 mice per group. *, 
p<0.01. 
 
We evaluated the delivery of Dox in tumors for the aforementioned groups by 
tracing the red fluorescence of Dox. Only a weak fluorescence signal in tumors was 
observed for mice treated with Dox-MuMVs (magnet −) and RGD-Dox-MuMVs 
(magnet −) (Figure 4.14b). The fluorescence was slightly higher for mice treated with 
Dox-MuMVs (magnet +). In contrast, the group of RGD-Dox-MuMVs (magnet +) 
exhibited the strongest fluorescence of Dox in tumors among all the groups. After in 
vivo imaging, the mice were sacrificed and tumor tissues were harvested for 
quantitative ex vivo imaging. Compared with the mice injected with Dox-MuMVs 
(magnet −), the fluorescence in tumor tissues exhibited a 1.6-, 1.3-, and 11.8-fold 
increase for the groups of Dox-MuMVs (magnet +), RGD-Dox-MuMVs (magnet −), 
and RGD-Dox-MuMVs (magnet +), respectively, indicating the enhanced delivery 
efficacy thanks to a synergetic magnetic and active targeting strategy (Figure 4.14c). 
Major organs of mice were also collected for ex vivo quantitative analysis of Dox 
biodistribution with and without targeting strategies (Figure 4.15). In the control groups 
(magnet −, RGD −), only 0.70% of injected Dox was observed at the tumor site while 
7.0% and 1.4% of Dox was found in liver and spleen, respectively. However, the 
accumulation of Dox in tumor significantly increased to ∼ 6.0% with combined 







Figure 4.15 Biodistribution of Dox after intravenous injection of Dox-MuMVs 
(magnet-) and RGD-Dox-MuMVs (magnet+) into subcutaneous U87MG tumor-
bearing mice. *, p<0.01. 
 
The rapid clearance of relatively large particles by the reticuloendothelial system 
(RES) is known to reduce the accumulation of particles in diseased sites.13,199 It is 
interesting that the fast accumulation of MuMVs in tumors via combination targeting 
strategies ensures less RES capture and enhanced delivery efficiency, although their 
size is larger than 200 nm. We presume that this can be attributed to the following two 
aspects. First, the MuMVs are composed of highly elastic vesicular membrane (in 
contrast to rigid solid NPs), which enables them to deform their shape and to penetrate 
into tumor tissues under an external magnetic field. This is partially confirmed by the 
fact that the MuMVs with a diameter of ∼ 260 nm can readily pass through channels 
with a diameter of 200 nm (Figure 4.16). Second, the magnetic force exerted on a single 
MuMV is directly proportional to the cumulative SPIONs in a vesicle. With the 
increase of vesicle size, more SPIONs can be loaded in the vesicle membrane and a 
stronger net magnetic force could be exerted to drive MuMVs to accumulate in tumors. 









Figure 4.16 SEM images of MuMVs (a) before and (b) after filtration through a 200 
nm filter 
 
We further investigated the therapeutic efficacy by monitoring the tumor volume 
change every 2 days over 16 days (Figure 4.14d). It was found that the mice treated 
with PBS buffer exhibited a rapid increase in the size of the tumors. Minor delay in 
tumor growth was observed in the mice treated with Dox or Dox-MuMVs (magnet −) 
due to the low delivery efficiency. Thanks to the active or magnetic targeting capacity, 
both RGD-Dox-MuMVs (magnet −) and Dox-MuMVs (magnet +) treated mice 
exhibited improved efficacy of tumor growth inhibition. In contrast, the tumor was 
nearly completely eradicated for the mice treated with RGD-Dox-MuMVs (magnet +). 
Moreover, the mice treated with RGD-Dox-MuMVs (magnet +) exhibited a much 
longer survival life without a single death or tumor reccurrence (over 30 days) as 





weight was observed for all the groups of mice during the therapeutic period (Figure 
4.14f), indicating minimal systemic toxicity of drug carriers. 
 
4.4 Conclusions 
In summary, we have developed a new class of MVs with tunable layers of densely 
packed SPIONs in the polymeric membrane for tumor-targeted imaging and delivery. 
The morphology of the vesicles could be controlled from monolayer, double layer to 
multilayer vesicles, and the membrane thickness increased significantly with increasing 
feeding ratio of PS-b-PAA to SPIONs. The MuMVs with a thicker membrane and 
higher SPIONs density were found to possess unique features such as enhanced 
contrast in MRI, high magnetization per vesicle, and tunable release profile of 
therapeutic agents. Upon intravenous administration, the MuMVs conjugated with 
RGD targeting moieties can be efficiently enriched at the tumor site in vivo with the 
assistance of an external magnetic field, thanks to the synergistic magnetic and active 
tumor targeting effect. The enhanced tumor accumulation of MuMVs enables the 
efficient imaging of tumors by MRI, tumor targeted delivery of payload and a resultant 
enhanced tumor inhibition. We envision that such MuMVs may find applications for 
imaging-guided delivery of therapeutic agents to patients with inoperable but shallow 









Chapter 5: Conclusions and Future work 
5.1 Conclusions 
The objective of this dissertation was to design and fabricate hybrid polymer-
inorganic nanoassemblies for biomedical applications. The HPINs naturally combine 
the complementary properties of inorganic NPs and polymers for improved 
performance in cancer imaging and therapy. 
In chapter 2, we demonstrate an enzyme-free signal amplification technique, based 
on plasmonic vesicles assembled from BCP-tethered GNPs as the membrane. The 
vesicles encapsulated Pd-Ir nanoparticles as peroxidase mimics for colorimetric assay 
of disease biomarkers with significantly enhanced sensitivity. Using human prostate 
surface antigen as a model biomarker, we demonstrated that the enzyme-free assay 
could reach a limit of detection at the femtogram/mL level, which is over 103-fold lower 
than that of conventional enzyme-based assay when the same antibodies and similar 
procedures were used. The enzyme-free technique we developed can be potentially 
extended to a variety of other enzymes-based diagnostic technologies beyond ELISA 
such as immunohistochemistry, Western blot, and point-of-care tests. Importantly, this 
technique is compatible with equipment and procedures of existing sensing 
technologies, making it practically useful for clinical diagnostics 
In chapter 3, we developed a universal approach for the grafting of BCPs onto 
hydrophobic inorganic NPs to trigger the assembly of NPs into hollow vesicles. This 
method relies on the attachment of BCPs onto OA/OAm capped NPs via a one-step 





thiols in BCPs are coupled into thioether linkage through radical addition, followed by 
the self-assembly of the BCP-tethered NPs into NVs. We demonstrated the assembly 
of various sized IONPs into magnetic vesicles with potentially enhanced magnetization 
due to the coupling between adjacent subunits. We also assembled Cu9S5, MnO and 
upconversion NPs into NVs after attachment of amphiphilic BCPs using the same 
procedures. Accordingly, this study provides a universal strategy for assembling OA 
or OAm-capped inorganic NPs into hollow NVs which may find a variety of 
applications in biological fields. 
In Chapter 4, we describe the fabrication of nanosized MVs comprising tunable 
layers of densely packed SPIONs in membranes via cooperative assembly of polymer-
tethered SPIONs and free PS-b-PAA. The membrane thickness of MVs could be well 
controlled from 9.8 to 93.2 nm by varying the weight ratio of PS-b-PAA to SPIONs. 
The increase in membrane thickness was accompanied by the enhanced magnetization 
and transverse relaxivity rate (r2) in MRI as a result of higher density of SPIONs in the 
polymeric membrane. Therapeutic agents such as Dox can be efficiently encapsulated 
in the hollow cavity of MVs and the release of payload can be tuned by varying the 
membrane thickness of nanovesicles. Upon intravenous injection, Dox-loaded MuMVs 
conjugated with RGD peptides could be effectively enriched at tumor sites due to 
synergetic effect of magnetic and active targeting. As a result, they exhibited drastically 
enhanced signal in MRI, improved tumor delivery efficiency of drugs as well as 
enhanced antitumor efficacy, compared with groups with only magnetic or active 





control by delivering imaging and therapy to organs/tissues that are not readily 
accessible by conventional delivery vehicles. 
 
5.2 Future work 
Although a variety of NP-based diagnostic and therapeutic agents are in clinical 
trials and many more are close to the goal, very few of them are hybrid assemblies. It 
is clear that a myriad of obstacles must be overcome before clinical translation can 
happen. There exist several barriers for the clinic translation of assembled nanohybrids 
in cancer theranostics. The relative sophisticated process of fabrication makes it 
difficult to ensure uniform formulation of nanohybrids from batch to batch in terms of 
the size, shape, drug loading, and surface of the materials. This can pose a significant 
obstacle to meet the food and drug administration (FDA) and/or european medicines 
agency (EMA) regulations to NP-based products. Furthermore, the development and 
manufacturing cost increases significantly with increasing the level of sophistication of 
the platform. As for economic consideration, a much lower return on investment 
becomes a big barrier to technology transfer and commercialization. 
As mentioned above, it is crucial to manufacture the hybrid assemblies in a 
controllable, scalable and economic way with enhanced performance in both imaging 
and therapy. From the diagnosis point of view, more effort should be made to further 
increase the sensitivity, reproducibility, and specificity of cancer diagnosis. This stems 
from current urgent needs for early diagnosis of cancer, better evaluation of the cancer 
stages, as well as real-time assessment of therapeutic outcome. For example, in our 





system could be realized by tuning the size of GV, loading amount of Pd-Ir NPs, 
particle release time and catalytic efficiency. For the next step, detection of clinical 
samples are the subjects of our future research. For effective cancer therapy, real time 
monitoring of the dosage of drugs delivered to target sites at specific times will provide 
guidance to optimize and tailor the formula for personalized medicine and maximize 
the therapeutic outcomes, considering the complexity of tumors and difference between 
individual patients. From this point of view, new imaging methods together with 
materials design that can enable drug monitoring in vivo in a simple and reliable manner 
are in urgent need. In our magneto-nanovesicles system, isotope labelling of delivery 
vehicles could be applied to quantify the stability, biodistribution profile, release 
kinetics and body clearance of the HPINs, which can help us predict treatment outcome 
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